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These are strange and difficult times—
the entire world is facing considerable 
financial challenges, while the issues 
of conflict, strife, starvation, and 
climate change have also not departed. 
Regrettably, health care tends to get 
short shrift in straitened circumstances 
and, within health care, priority is often 
given to the more acute and “dramatic” 
illnesses, while common, important, 
debilitating, but “unexciting” disorders 
(among which many of the most 
common digestive disorders rank), and 
the many patients who suffer from them, 
are ignored. This is not only unfortunate 
but also short-sighted, given the impact 
of these conditions on the young and 
active during what should be the most 
productive years of their lives.
It is most appropriate, therefore, 
that the World Gastroenterology 
Organisation (WGO) has chosen irritable 
bowel syndrome (IBS) as its theme for 
World Digestive Health Day 2009. This 
is truly a global disorder that affects 
millions worldwide, many of whom 
suffer in silence. The true importance 
of IBS in gastroenterology, medicine, 
and public health is amply and vividly 
illustrated by the tremendous response 
from national societies around the 
globe to this topic. IBS has proven to 
be a galvanizing World Digestive Health 
Day theme for medical practitioners, 
patients, and the public alike. WGO will 
be playing a truly global role on World 
Digestive Health Day—energizing 
member societies, supporting their 
activities, and generating supportive 
materials in a most collaborative 
manner. World Digestive Health Day 
on 29 May 2009, and indeed the 
entire year, will bring IBS into rightful 
prominence and will hopefully promote 
a better understanding of the condition 
and lead to progress in diagnosis and 
management.
The “global crisis” presents challenges 
to WGO. As each nation strives to 
address its own economic and social 
problems, global issues fade into the 
gloom, and funding becomes ever 
more difficult to source for programs 
such as those that WGO supports 
around the world (Train the Trainers, 
Training Centers, Global Guidelines, 
International Digestive Cancer Alliance, 
Outreach). It is most appropriate that 
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  Editorials
Welcome to the second electronic 
edition of World Gastroenterology 
News! Our first issue was uniformly 
well-received. Emboldened by this 
positive feedback, we are exploring 
the possibilities for web-based learning 
opportunities. Keep a look-out for these 
new sections—such as embedded 
videos demonstrating new procedures—
in the upcoming issues.
It is no accident that the Scientific 
Section of this issue of WGN has 
a distinctly pancreatic “flavor.” As 
a card-carrying pancreatologist, I 
make no apologies for three articles 
on my favorite subject! Professors 
René Lambert and Robert Kurtz have 
contributed a detailed review of tumors 
of the exocrine pancreas. Clearly, the 
most vexing is adenocarcinoma of the 
pancreas, which stands almost alone 
amongst gastrointestinal malignancies 
as being a cancer with little hope of cure. 
When so many other once-fatal cancers 
are now eminently treatable, and often 
curable, why has pancreatic cancer 
remained such a predictable killer? 
Until recently, pancreatic cancer has 
not been a disease attracting charitable 
funding (compare it, for example, to 
breast cancer, childhood leukemia 
and, especially, AIDS). Deaths from 
pancreatic cancer among celebrities 
(such as “Bonanza” actor Michael 
Landon and Italian tenor Luciano 
Pavarotti) and news of others living with 
the disease (e.g., U.S. Supreme Court 
Judge Ruth Bader Ginsberg and actor 
Patrick Swayze) have spiked public 
interest, but a concerted effort and major 
research funding will be needed to 
“crack” this particular killer. Inadequate 
intravenous hydration is the silent killer 
in patients with severe acute pancreatitis 
(SAP), contributing to pancreatic 
necrosis, kidney failure, and other 
systemic manifestations of the disease. 
Dr. Scott Tenner of the State University 
of New York has been a leading 
advocate of aggressive intravenous 
hydration in these cases. Dr. Tenner 
and his colleague Dr. Badalov outline 
for us the fluid regimen that should be 
used in cases of predicted and actual 
SAP—information that (to the best 
of my knowledge) has not previously 
been promulgated in journal form. 
Finally, pancreatologist extraordinaire 
Dr. Bill Brugge and his colleague Dr. 
Saleemuddin from the Massachusetts 
General Hospital in Boston review 
the hot topic of medical therapy for 
autoimmune pancreatitis.
We intend to have future Scientific 
Sections dedicated to particular 
diseases and management themes.  
I would welcome readers’ suggestions 
for subjects we should look at.
Irritable bowel syndrome (IBS) is “big” 
this year, and in recognition of that fact, 
we are pleased to bring you four papers 
on the subject. Dr. Per Olav Vandvik, 
Associate Professor of Medicine at 
the University of Oslo, discusses 
current challenges in the diagnosis and 
treatment of IBS. Dr. Max Schmulson 
of the Universidad Nacional Autónoma 
de México tells us “what we know 
about IBS in Mexico.” Finally, the WGO 
librarian, Justus Krabshuis, continues his 
outstanding series on gastroenterology 
on the Internet, with an overview of how 
to search intelligently for IBS-related 
publications. Last, but by no means 
least, Irritable Bowel Syndrome: A Global 
Perspective presents the highlights of 
WGO’s Global Guideline for IBS.
The year 2009 seems to be whizzing 
by, and in the blink of an eye it will be 
the end of the year and time for the next 
World Congress of Gastroenterology, to 
be held in London. In this issue of WGN, 
Dr. Michael Farthing assures us that 
this will be an outstanding international 
meeting, with something for everyone, 
including a live endoscopy course 
featuring procedures beamed in from no 
less than three countries!
Under the heading “Great Mentors,” I 
have kicked off a little series on the role 
of mentors in gastroenterology. Mentors 
for young researchers and for clinical 
and procedural trainees in particular are 
becoming an endangered species—let’s 
help preserve the species by honoring 
them. I have already received invited 
contributions to this series that will 
appear in future issues of WGN, but I 
would be very happy to have more. Had 
a great mentor, or mentors? Let’s hear 
about her or him!
And finally, I would greatly appreciate 
feedback from our readers about the 
current format and content of WGN. Now 
that we are electronic, (almost) anything 
is possible! Let me know what you would 
like to see in the journal.
Message from the Editor
John Baillie, B. Sc (Hons), MB, 
Ch.B, FRCP, FASGE, FACG
Wake Forest University Health Sciences  
Winston-Salem, North Carolina, USA
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WGO has therefore established the 
WGO Foundation to raise funds and 
secure the future of its programs. We 
would ask all of you, as individuals, 
members of national societies, or as 
acquaintances of funding agencies or 
philanthropists, to support the WGO 
Foundation. Our future is your future!
Despite these challenges, WGO 
has been even more active: a new 
TTT program on “Trial Design” was 
most successfully presented in the 
beautiful city of Dubrovnik, Croatia; 
a full TTT will take place in Santiago, 
Chile in September; IDCA will present 
or participate in several important 
programs; two new guidelines are 
about to appear; and major equipment 
donations were delivered to our training 
centers in Suva (Fiji) and Ribeirão 
Prêto (Brazil). WGO has not reneged 
and will not renege on its mission and 
will continue to pursue its goals with as 
much vigor and rigor as ever. Join us  
in these efforts!
Of course, the pinnacle of our year 
will be GASTRO 2009 in London 
in November, which will represent 
the culmination of a remarkable 
collaboration between WGO, UEGF, 
OMED, and the British Society of 
Gastroenterology to present a world 
congress with a European flavor in  
a British atmosphere. The excitement 
around GASTRO 2009 worldwide 
is really palpable and—having seen 
the program and knowing of all the 
work that has gone into developing it, 
including the working parties, Young 
Clinicians’ Program, and the various 
named lectures (distinctive features  
of world congresses)—I know that  
“this excitement is fully justified.  
Come to London in November. You  
will be richly rewarded! 
Eamonn M.M. Quigley 
WGO President 2005-2009
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Introduction
Pancreatic tumors are classified 
on the basis of cell differentiation 
and immunostaining. Cancer of the 
exocrine pancreas develops from ductal 
epithelial cells or from acinar cells.
Ductal adenocarcinomas represent 
more than 90% of all pancreatic 
carcinomas. Other neoplastic 
ductal lesions with a variable risk 
of malignancy include areas of flat 
hyperplasia in the ductal epithelium, 
with successive mutations of KRAS, 
p53, p16, DPC4, and three categories 
of cystic neoplastic lesion: mucinous 
cystic adenomas, intraductal papillary 
mucinous neoplasms (IPMNs), and 
serous cystadenomas, which have a 
very low risk for malignancy.
Nonductal adenocarcinomas 
develop from the acinar cells and 
are relatively rare. In acinar cell 
carcinoma, acinar differentiation 
is confirmed by zymogen granules 
positive for periodic acid–Schiff 
and immunostaining for trypsin; the 
tumor is usually large at detection 
(around 10 cm) and mutations of 
the β-catenin gene are frequent. 
Pancreatoblastoma is another highly 
malignant nonductal carcinoma, which 
occurs in children under the age of 
10 years. The genetic alterations of 
ductal carcinoma are not present, and 
alteration in the β-catenin pathway 
is frequent. Solid pseudopapillary 
neoplasms, which are borderline 
lesions with low-grade malignancy, 
are also classified in this group.
Endocrine pancreatic tumors, 
including multiple endocrine neoplasia 
type 1 (MEN-1), represent a third 
group derived from the islets of 
Langerhans. Misclassification may 
occur in these cases in the presence 
of mixed exocrine–endocrine tumors, 
with combinations such as acinar–
endocrine or acinar–ductal–endocrine.
Tumors of the pancreas are 
also classified on the basis of 
their morphology—solid or cystic. 
Solid tumors include ductal 
adenocarcinoma, acinar carcinoma, 
and borderline lesions: solid 
pseudopapillary tumor and endocrine 
neoplasia. Cystic pancreatic masses 
are increasingly being recognized, 
as a direct consequence of the 
more widespread use of imaging 
technology. Nonneoplastic and 
inflammatory cystic masses—
pseudocysts—are of course by far 
the most common pancreatic cystic 
lesions, associated with a history 
of pancreatitis. Cystic neoplasms, 
which represent 10–15% of cystic 
masses of the pancreas, include 
serous cystadenomas, mucinous 
cystic neoplasms, and intrapancreatic 
mucinous neoplasms (IPMNs). 
Finally, some solid tumors may have 
a cystic morphology; this occurs in 
pseudopapillary neoplasm, acinar 
carcinoma (which is then classified 
as an acinar cystadenocarcinoma), 
and some endocrine-secreting 
tumors (e.g., insulinoma, gastrinoma, 
glucagonoma).
The burden of  
pancreatic cancer
The epidemiology and burden 
of pancreatic cancer relate to 
ductal adenocarcinoma—a dismal 
disease with a poor prognosis and 
early lymphatic and hematogenic 
dissemination. At the time of diagnosis, 
less than 10% of the lesions present 
as localized tumors, and the patients’ 
5-year survival is still not over 5%. In 
the International Agency for Research 
on Cancer (IARC) Globocan 2002 
database, the worldwide burden of 
pancreatic cancer for the year 2005 is 
estimated at 232,000 new cases and 
227,000 deaths [1]. Of the new cases, 
125,000 affect men and 107,500 
women. In the same database, cancer 
of the pancreas ranks twelfth for the 
frequency of cancer and eighth for 
mortality.
Incidence. The estimated numbers 
of annual cases occurring in various 
regions are shown in Table 1, which 
is derived from the IARC database 
[1]. Geographic variations in the 
Cancer of the exocrine pancreas
René Lambert, MD and Robert C. Kurtz, MD
René Lambert, MD, IARC, Lyons, France 
Robert C. Kurtz, MD, Memorial Sloan-Kettering  
Cancer Center, New York, New York, USA
Region Cases (n)
North America 34900
South America 13400
Central America  4200
Africa (5 areas)  7100
Europe (with Russia) 78000
Asia (with Japan) 91000
Table 1. Estimated numbers of incident 
cases of cancer of the pancreas (both 
sexes) occurring in 2002 in various 
regions of the world, from the International 
Agency for Research on Cancer (IARC) 
Globocan 2002 database [1].
estimated age-adjusted incidence per 
100,000 (age-standardized rate, ASR) 
for pancreatic cancer are shown for 
men and women in Fig. 1 from the 
same database. The figures are higher 
in North America, European countries 
and Russia, Japan, and Argentina, and 
much lower in developing countries in 
Africa, as well as in India and China. 
The observed ASR for pancreatic 
cancer in cancer registries is shown 
for some countries around the world in 
Table 2 and is slightly lower in women 
than in men [2]. In the USA, slight 
differences in the ASR incidence are 
shown in the Surveillance Epidemiology 
and End Results (SEER) registries for 
different ethnic groups (Table 3) [3]. 
The highest values occur in persons of 
African origin and the lowest in those 
with Native American and Asian ethnic 
backgrounds.
Mortality. A comparison between the 
estimated incidence and mortality from 
pancreatic cancer is also available in 
the IARC database [1] and is shown 
for three countries in Table 4. The 
annual number of deaths is equivalent 
to the annual number of new cases; 
this confirms that the average survival 
is not more than 1 year from diagnosis. 
The age-adjusted mortality rate of per 
100,000 in men and in women is very 
similar to that of ASR incidence, as 
shown in Table 3; the difference is 
minimal in men but more marked in 
women.
Survival. The prognosis with 
pancreatic carcinoma is very poor, 
and the relative 5-year survival in 83 
cancer registries and 23 European 
countries in the EUROCARE-4 study 
was 5.5% for both sexes in the period 
1995–99 [4]. Time trends in the 5-year 
relative survival have been analyzed 
for the period 1975–2000 in the SEER 
registries and are shown in Table 5; 
a slight improvement is evident, with 
figures increasing from 3.6% to 5.2% 
in men and 2.1% to 5.4% in women [3].
Causal factors in sporadic 
pancreatic cancer
The identification of environmental 
factors in carcinogenesis is of major 
help for developing cancer prevention 
policies. Unfortunately, most case–
control and cohort studies conducted 
for pancreatic cancer have proved 
inconclusive.
Smoking. This is the only significant 
promotor factor. In a meta-analysis 
conducted recently by Iodice et al. [5], 
the risk of pancreatic cancer is increased 
at 1.74 for current smokers and 1.2 for 
former smokers. Overall, smoking causes 
a 75% increase in risk of pancreatic 
cancer. Taking into account the 
proportion of smokers in the population, 
the attributable risk of smoking for 
pancreatic cancer is around 20%.
Alcohol, coffee, tea. The data from 
two very large cohort studies in the 
USA, the Health Professionals Follow-
Up Study and the Nurses’ Health Study, 
with 1,907,222 person-years of follow-
up, have been revised by Michaud et al. 
[6]. They do not support any association 
between coffee or alcohol intake and 
the risk of pancreatic cancer. A similar 
negative conclusion emerged from the 
European Prospective Investigation 
into Cancer and Nutrition (EPIC) and 
from the Collaborative Cohort Study for 
Evaluation of Cancer Risk (JACC study) 
in Japan. The data in the population-
based cohort study in Japan (JPHC 
study) do not support any impact of 
green tea consumption on the risk of 
pancreatic cancer.
Physical activity and obesity. 
Occupational or leisure-time physical 
activity has been associated with a 
lower risk for pancreatic cancer in 
several studies, but a systematic review 
of the literature has not provided strong 
evidence for an association. In a meta-
analysis conducted by Larsson et al. on 
the role of obesity, a slight association 
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Fig 1. Regional variations in the age-adjusted incidence per 100,000 of cancer of the 
pancreas presented in a world map, for men (1a) and women (1b). (From the International 
Agency for Research on Cancer Globocan 2002 database) [1].
(1a) Incidence of Pancreas cancer: ASR (World) - Male (All ages)
< 1.3
< 2.3
< 4.2
< 7.2
< 12.1
(1b) Incidence of Pancreas cancer: ASR (World) - Female (All ages)
< 1.1
< 1.7
< 3.5
< 4.6
< 11.4
was observed, with an estimated 
relative risk of pancreatic cancer (per 
5 kg/m2) of 1.12  [7].
Fruit and vegetables. Case–control 
studies have suggested that higher 
consumption of fruit and vegetables, 
including citrus fruits, is associated 
with a lower risk of pancreatic cancer, 
but cohort studies do not support 
this association. No protection 
against pancreatic cancer from the 
consumption of fruit and vegetables was 
demonstrated in the very large European 
prospective study cohort (EPIC).
Sugar. It has been hypothesized that 
hyperglycemia, hyperinsulinemia, and 
insulin resistance are involved in the 
development of pancreatic cancer, but 
epidemiologic studies on the role of 
added sugar or sugar-sweetened foods 
and beverages are inconclusive. In a 
large study with a 7.2-year follow-up 
conducted in the USA, consumption 
of sugar was not associated with 
pancreatic cancer.
Diabetes. Two types of diabetes are 
associated with pancreatic diseases. 
Hyperinsulinemia and peripheral insulin 
resistance (type 2 diabetes) are the 
prevailing diabetic traits in pancreatic 
cancer, whereas reduced islet cell 
mass and impaired insulin secretion 
occur in chronic pancreatitis (type 1 
diabetes). It has been suggested that 
pancreatic cancer causes diabetes. 
Recognition of new-onset diabetes as 
an early manifestation of pancreatic 
cancer could lead to the diagnosis of 
early-stage pancreatic cancer. New-
onset hyperglycemia could be used 
as a screening tool to identify people 
with asymptomatic pancreatic cancer; 
however, the success of this method 
depends on our ability to differentiate 
pancreatic cancer-associated diabetes 
from the more common type 2 diabetes.
Hereditary factors
The occurrence of at least two cases 
of pancreatic cancer in first-degree 
relatives of a family suggests a 
familial aggregation of cases. This 
situation is present in almost 10% of 
cases and has analyzed by Geenen 
and Kaul in another issue of WGN. 
Pancreatic cancer can occur in 
genetic hereditary syndromes for other 
categories of tumor, with an identified 
germline mutation: BRCA1/BRCA2 
gene mutations and breast cancer, 
mismatch repair gene (MLH1, MSH2) 
mutations and hereditary nonpolyposis 
colorectal cancer (HNPCC) syndrome, 
STK-11/LKB1 gene mutation, and 
Peutz–Jeghers syndrome, CDKN2A 
gene mutation and the familial atypical 
multiple mole-melanoma (FAMMM) 
syndrome, in which melanomas 
are associated with benign moles. 
Pancreatic cancer also occurs in the 
hereditary pancreatitis syndrome, in 
which mutations in SPINK1/PRSS1 
genes play a role. This syndrome is 
characterized by recurrent attacks of 
acute pancreatitis. Finally, aggregation 
of pancreatic cancer occurs in the 
familial pancreatic cancer syndrome, 
where the mutation is unknown. 
Familial pancreatic cancer can be 
defined as an inherited predisposition 
based on family clustering, with two or 
more blood relatives with pancreatic 
adenocarcinoma of ductal origin. As 
shown by Hruban et al. [8], a family 
history of pancreatic cancer is present 
in about 10% of patients with this 
disorder.
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Men Women
Chile: Valdivia 4.2 3.8
USA: SEER, 14 registries 7.9 5.9
China: Hong Kong 4.5 3.1
China: Shanghai 7.5 5.3
Japan: Osaka 9.3 5.4
Korea: Seoul 8.7 5.0
Denmark 7.8 6.6
France: Calvados 7.6 5.2
Italy: Veneto 9.9 7.0
Table 2. Observed age adjusted 
incidence rate per 100,000 of 
cancer of the pancreas in cancer 
registries from various countries 
during the period 1998–2002 
(from Cancer Incidence in Five 
Continents, vol. 9, Lyons: IARC, 
2007; IARC Scientific Publications 
no. 160) [2].
Men Women
Incidence Mortality Incidence Mortality
All ethnic groups 13.0 12.2 10.3 9.3
White 13.0 12.1 10.0 9.0
Black 16.2 15.4 14.3 12.4
Asian 10.1 8.0 8.2 6.9
Native Americans 10.9 8.6 8.2 7.2
Hispanic 10.9 9.1 10.3 7.6
Table 3. Observed age-adjusted incidence and mortality per 100,000 of cancer of the 
pancreas by sex and ethnic group in cancer registries in the USA (2001–2005 period, 
from 17 Surveillance Epidemiology and End Results registries) [3].
Country Cases (n) Deaths (n)
France  5300  7250
USA 31650 30300
Japan 19900 20100
Men Women
1975 3.6 2.1
1985 2.6 3.9
1995 3.1 4.5
2000 5.2 5.4
Table 4. Comparison of the estimated 
numbers of incident cases and of 
deaths from cancer of the pancreas 
(both sexes) occurring in 2002 in 
three countries, from the International 
Agency for Research on Cancer (IARC) 
Globocan 2002 database [1].
Table 5. Time trends in the 5-year 
relative survival by sex in cancer 
registries in the USA (1975–2000 
period, from nine Surveillance 
Epidemiology and End Results 
registries) [3].
Scientific news
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Several registries are collecting 
data on hereditary pancreatic cancer. 
The EUROPAC registry is based in 
Liverpool, United Kingdom, and there 
are about a dozen hereditary pancreatic 
cancer registries established in the 
USA, including those at the Johns 
Hopkins Medical Center and the Mayo 
Clinic. A Familial Pancreatic Tumor 
Registry has been established at the 
Memorial Sloan-Kettering Cancer 
Center in New York. Over 1500 
individuals have been recruited to the 
registry, including pancreatic cancer 
patients with multiple affected relatives, 
healthy individuals with multiple affected 
relatives, healthy controls, patients 
with sporadic pancreatic cancer, and 
patients with IPMNs. Because of the 
association of BRCA mutations and 
pancreatic cancer, individuals with 
a BRCA1 or BRCA2 mutation and a 
family history of pancreatic cancer are 
also recruited. The registry has served 
as a resource for a number of ongoing 
studies, including epidemiology of 
pancreatic cancer, screening at-risk 
relatives for pancreatic neoplasia, and 
genome-wide association studies.
Premalignant neoplastic 
lesions
Pancreatic intraepithelial neoplasia 
is a precursor of ductal carcinoma. 
In surgical specimens, areas of flat 
hyperplasia with columnarization of 
ductal epithelium and ductal papillary 
hyperplasia are found adjacent to 
invasive carcinoma. The progression 
to malignancy is accompanied at an 
early stage by mutations in the KRAS 
oncogene, followed by mutations of 
p53, p16, and DPC4/ SMADD4 tumor 
suppressor genes.
Benign cystic neoplasms are tumors 
with ductal differentiation that have a 
variable potential for malignancy. Serous 
cystadenomas (SCAs) occur mainly 
in middle-aged women and account 
for 30% of primary cystic neoplasms; 
depending on their size, they are 
classified as microcystic or macrocystic. 
They are usually benign; progression to 
serous cystadenocarcinoma is very rare. 
Mucinous cystic neoplasms (MCNs) 
occur predominantly in middle-aged 
women and account for 45% of primary 
cystic neoplasms. Their appearance is 
often that of a cyst within a cyst, without 
communication with the pancreatic 
duct. The presence of ovarian stroma 
in the tumor is strongly suggestive of 
the diagnosis. They are classified as 
borderline neoplastic lesions, which 
progress in 5–35% of cases to mucinous 
cystadenocarcinomas. Intraductal 
papillary mucinous neoplasms (IPMNs) 
occur more often in men and account 
for 25% of primary cystic neoplasms. 
Their appearance is that of a grape 
with cysts. IPMNs arise from the main 
pancreatic duct or from its branches, 
and communicate with the duct. IPMNs 
arising from the main pancreatic duct 
carry a higher risk of malignancy (60–
90%) than those arising from collateral 
branches (around 5%).
Solid pseudopapillary neoplasms are 
tumors with nonductal differentiation, 
composed of partially encapsulated 
sheets of polygonal cells with a cystic 
morphology. They stain positive for 
the markers vimentin and CD10, and 
are negative for ductal and endocrine 
markers. Solid pseudopapillary 
neoplasms are more frequent in 
women and are classified as borderline 
malignant lesions.
Diagnosis
The dramatic progress in radiographic 
imaging and endoscopic exploration 
of the pancreas has led to a much 
more reliable classification of cystic 
lesions of the pancreas and made 
it possible to distinguish malignant 
or benign neoplastic lesions from 
pancreatitis. Percutaneous biopsies of 
a solid pancreatic mass performed with 
ultrasound or computed tomography 
(CT) guidance provide tissue 
specimens for histology. Overall, there 
has been some progress in the early 
detection of pancreatic cancer, but 
survival after treatment for pancreatic 
cancer remains depressingly poor.
Imaging
Transabdominal ultrasound, which 
outside the U.S. is still the basic 
screening procedure, may detect 
dilation of the biliary duct and even of 
the main pancreatic duct (of Wirsung), 
but the pancreas itself is often poorly 
visible due to gas in overlying bowel 
segments. The procedure is very 
operator-dependent. High-resolution 
helical CT scanning of the abdomen 
with intravenous contrast enhancement 
is now widely available. The size and 
the location of cystic neoplasms in the 
head, body, or tail of the pancreas can 
be determined, as well as the presence 
of intracystic masses or mural nodules 
and communication with the pancreatic 
duct. Serous cystic adenomas often 
show a honeycomb pattern, with 
multiple, small cysts within a large 
cyst and a central stellar scar that may 
calcify. Mucinous cystic neoplasms are 
often large and multilocular; IPMNs 
produce the characteristic image of a 
bunch of grapes containing numerous 
small cysts, communicating with a 
dilated pancreatic duct or its branches; 
mural nodules or intracystic masses are 
frequent. Another recently introduced 
imaging test is magnetic resonance 
cholangiopancreatography (MRCP). 
Single-shot, fast spin-echo MR images 
can detect small pancreatic cysts 
with more precision than abdominal 
ultrasound or CT scanning.
Endoscopy
Endoscopic retrograde 
cholangiopancreatography (ERCP) 
is the most sensitive technique for 
detecting a communication between 
a cyst and the pancreatic ducts 
occurring in IPMN. The diagnosis 
is also suggested when mucus is 
seen leaking from a patulous papilla. 
Pancreatoscopy for direct observation 
of the tumoral lesions in the pancreatic 
duct is now possible using small-caliber 
flexible endoscopes (miniscopes). 
Endoscopic ultrasonography (EUS) is 
increasingly available for the diagnosis 
and management of pancreatic 
neoplastic lesions. As an alternative to 
conventional echo endoscopes, flexible 
high-frequency (20-MHz) catheter 
probes can be introduced through the 
working channel of an endoscope. In 
Scientific news
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the presence of mucinous neoplasms, 
malignancy can be predicted with an 
accuracy of 50% with EUS, based on 
the following criteria: size greater than 
2 cm, pancreatic duct dilation, wall 
calcifications, and masses or mural 
nodules. In specialized centers, EUS 
is used to aspirate cyst fluid using fine-
needle aspiration (FNA).The aspirated 
fluid is evaluated for cytology, with 
cuboidal cells staining for glycogen, 
in serous cysts and columnar cells 
staining for mucin in mucinous cysts. 
Two biological markers are helpful 
for differentiating between mucinous 
and serous neoplastic lesions: 
amylase activity is low in serous 
neoplasms and high in mucinous 
ones; the carcinoembryonic antigen 
(CEA) concentration is below the 
threshold value of 192 ng/mL in serous 
neoplasms and above that value in 
mucinous ones.
Screening and surveillance
Guidelines recommend surveillance 
using repeated imaging procedures 
(CT, MRI, EUS) in individuals diagnosed 
as having an IPMN, which is associated 
with a significant risk of malignant 
development.
No screening strategy for early 
detection of sporadic pancreatic cancer 
is recommended in asymptomatic 
persons. On the other hand, screening 
and surveillance at regular intervals 
are recommended for those with an 
increased risk for pancreatic ductal 
adenocarcinoma. This applies to 
inherited genetic syndromes, hereditary 
pancreatitis, and familial pancreatic 
cancer. In the USA, pancreatic cancer 
has a low prevalence; however, 
members of families with familial 
pancreatic cancer (FPC) are an 
identifiable at-risk group for whom 
screening could be both feasible 
and beneficial. A screening program 
was started at the Memorial Sloan-
Kettering Cancer Center in 2002, 
using cross-sectional imaging as the 
primary screening tool, followed by 
endosonography if any pancreatic 
abnormalities were found. IPMN 
was the most common pancreatic 
lesion found in the FPC population 
and may very well represent the 
pancreatic cancer precursor lesion in 
this population. This finding is similar 
to what was reported by Canto et al. 
[9] from Johns Hopkins in their FPC 
screening study. Clearly, it is too early 
to determine the long-term benefit from 
screening members of FPC families.
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Regardless of etiology, the 
pathogenesis of acute pancreatitis 
results in the extravasation of 
liters of intravascular fluid into the 
peritoneum. These losses manifest in 
the development of pancreatic ascites, 
hypotension, tachycardia, and further 
destruction of the pancreas, also 
referred to as “pancreatic necrosis.” 
Impairment of the microcirculation of the 
pancreas appears to lead to pancreatic 
necrosis. A vicious cycle develops 
in which pancreatic inflammation 
leads to extravasation of protein-rich 
intravascular fluid into the peritoneum. 
The intravascular hypovolemia that 
accompanies acute pancreatitis 
subsequently leads to a decrease 
in pancreatic blood flow. Pancreatic 
ischemia leads to the activation of 
inflammatory mediators. The decreased 
blood flow also causes stasis and 
the development of thrombi, leading 
to subsequent necrosis, which then 
exacerbates the inflammatory process. 
The association of hemoconcentration, 
in which the hematocrit (HCT) level 
rises, with pancreatic necrosis 
illustrates this process (Fig. 1).
Vigorous intravenous hydration 
leads to hemodilution and relief of 
hemoconcentration. This translates into 
direct benefits for the patient with acute 
pancreatitis. A decreased hematocrit is 
associated with mild disease. Also, a 
falling hematocrit during the first 24 h of 
care leads to a decrease in morbidity. 
Clinical studies with aggressive plasma 
volume expansion using intravenous 
dextran to promote hemodilution have 
suggested efficacy in preventing severe 
disease. Although dextran is not used 
clinically at present, isotonic saline is 
our practical alternative. It appears that 
vigorous intravenous hydration early 
in the course of acute pancreatitis can 
prevent the development of necrosis.
The goal in managing patients with 
acute pancreatitis is to decrease the 
hematocrit, achieve hemodilution, 
decrease the blood urea nitrogen (BUN) 
and creatinine, and promote renal 
blood flow. By preventing intravascular 
depletion of fluid and promoting 
pancreatic blood flow, pancreatic 
perfusion is maintained. By maintaining 
pancreatic perfusion, pancreatic 
necrosis and the complications of 
pancreatitis leading to severe disease 
are prevented (Fig. 2).
Too often, patients with acute 
pancreatitis are given suboptimal 
intravenous hydration, resulting in 
pancreatic necrosis and organ failure. 
How much fluid should be given? 
Part of the answer is related to the 
amount of losses the patient presents 
with, and the other part is related to 
continuing losses due to the ongoing 
pancreatic inflammatory process. A 
patient who presents with hypotension 
and tachycardia clearly needs more 
aggressive hydration than one who is 
normotensive with a normal baseline 
pulse. Regardless of this, clinicians 
must suspect that a patient with acute 
pancreatitis will subsequently develop 
serious intravascular fluid losses. One 
of the markers of severity previously 
defined by Ranson and colleagues is 
related to intravascular losses. Ranson 
et al. (1976) found that sequestration 
(i.e., peritoneal pancreatic ascites) of 
over 6 L of fluid during the first 48 h was 
How much fluid should be given during the 
initial management of acute pancreatitis?
Fig 1. In acute pancreatitis, hypoperfusion to 
the pancreas results in increased pancreatic 
necrosis, which leads to the release of 
proinflammatory mediators, which in turn 
exacerbates hypoperfusion, leading to greater 
necrosis and a rise in hematocrit (HCT).
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an independent predictor of severity. 
A patient with mild disease routinely 
would lose 3–5 L into the peritoneum.
Not including baseline losses, 
how much intravenous hydration is 
needed? If we use the Ranson upper 
limit of severity of an amount of 6 L 
(expected losses), added to the minimal 
intravenous fluid requirements of a 70-
kg person during the first 48 h (8 L), 
intravenous hydration should be at least 
300–350 mL per hour initially. The rate of 
hydration is likely to be more important 
during the first 24 h, when a rising HCT 
has been shown to correlate closely with 
severe disease. The rate of hydration 
should be titrated to the hematocrit. The 
goal is to decrease the hematocrit 5–10 
points during the first 24 h.
There are multiple caveats to the 
basic assumption of the initial rate 
of hydration. In a patient with acute 
pancreatitis, in order to guide hydration, 
the clinician must take into account 
the patient’s age, underlying cardiac, 
renal and pulmonary disease, and body 
mass index (BMI). Whereas all elderly 
patients need to be followed closely, 
those with renal and cardiovascular 
disease may need intracardiac 
monitoring to guide hydration and 
prevent congestive heart failure. Over 
the last several years, we have learned 
that patients who are obese, with an 
elevated BMI, are at increased risk 
of pancreatic necrosis, organ failure, 
and death. It is likely that the reason 
why obese patients (those with an 
elevated BMI) are more likely to have 
complicated disease is directly related 
to inadequate intravenous hydration. 
When one considers that a 100-kg 
male who is 1.93 m (6 feet 4 inches) 
tall needs a baseline of almost 400 mL/
h of hydration, it becomes apparent 
that if the same patient develops 
acute pancreatitis, he is far more likely 
to receive inadequate hydration in 
comparison with a normal person.
Which type of fluid should be used? 
In order to promote perfusion and 
maintain intravascular pressure, the 
fluid should be isotonic. Hypertonic 
solutions, which would maintain or 
even increase intravascular pressure, 
are being studied but are considered 
experimental. The two widely available 
isotonic solutions are “normal” (0.9%) 
saline and lactated Ringer’s solution.
There are several theoretical benefits 
to using the more pH-balanced lactated 
Ringer’s solution for fluid resuscitation 
in comparison with normal saline. 
Although both are crystalloid solutions, 
the development of non-anion gap, 
hyperchloremic metabolic acidosis 
associated with the infusion of large 
volumes of normal saline has been 
well described. On the basis of the 
metabolic acidosis associated with large-
volume infusion of normal saline and 
the available evidence suggesting that 
the inflammation associated with acute 
pancreatitis is a pH-dependent process, 
resuscitation with lactated Ringer’s 
solution may have significant benefits 
over normal saline in the early treatment 
of patients with acute pancreatitis.
Summary
In a patient who is otherwise healthy, 
presenting as normotensive with 
minimal tachycardia, intravenous 
hydration with lactated Ringer’s solution 
at 250–350 mL/h, depending on BMI, 
should be initiated and maintained 
until the acute inflammatory process 
resolves. The goal is to decrease the 
hematocrit by at least three points 
from baseline (below 44%). On the 
basis of animal studies, the goal may 
be to decrease the hematocrit to the 
mid-30% range. If the patient presents 
as hypotensive and tachycardic, 
intravenous hydration should be much 
more aggressive—e.g., 500 mL/
h minimum. Currently, there is no 
specific therapy available to attenuate 
the inflammatory response in acute 
pancreatitis. Instead, practice guidelines 
universally recommend supportive care 
with intravenous hydration.
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Fig 2. Progression to pancreatic necrosis. These images show 
the progression of pancreatic necrosis in a patient with acute 
pancreatitis. The dynamic CT scan performed on day 1 shows 
opacification of the kidneys, spleen, and pancreas. In contrast, 
a repeat CT scan on day 3 shows opacification of the kidneys 
and spleen, but no pancreatic opacification. These images 
demonstrate a loss of pancreatic perfusion between days 1 and 
3 of the disease. This patient was poorly hydrated (150 mL/h) 
and developed adult respiratory distress syndrome (ARDS), 
renal failure, and had a rise in HCT from 42% to 46%.
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Introduction
The mainstay of medical therapy 
for autoimmune pancreatitis (AIP) is 
administration of oral corticosteroids. 
A variety of regimens have been 
described and used, but there is 
a lack of consensus regarding 
duration, dosing, and alternatives. 
Although corticosteroid therapy 
is highly effective, supplementary 
therapy is important in patients who 
have suffered from side effects or 
complications of corticosteroids. The 
role of immunosuppressive agents 
has recently been explored in a small 
number of patients. We have reviewed 
the available literature on the medical 
therapy of autoimmune pancreatitis and 
compared it to surgical therapy.
Methods
A text-word literature review was 
performed using the PubMed and 
Medline databases. Terms including 
“autoimmune pancreatitis,” “treatment 
of autoimmune pancreatitis,” and 
“management of autoimmune 
pancreatitis” were used for a 
comprehensive search over the past 
20 years. Published manuscripts 
providing original reports of medical and 
surgical therapy of AIP in peer-reviewed 
journals were critically reviewed. 
Responses (clinical, radiologic, and 
serologic) to the regimens described 
were compiled in a table format. Nine 
manuscripts describing therapy for AIP 
in 101 patients were critically reviewed 
for the dose, duration of therapy, and 
alternatives to corticosteroid therapy. 
The surgical therapy was also reviewed 
and used as a comparison.
Critical literature review
Autoimmune pancreatitis (AIP) 
is a form of chronic pancreatitis 
characterized by lymphoplasmacytic 
cellular infiltration of the pancreas, as 
well as other organs. The infiltration 
may involve the ducts, parenchyma, 
or both. Although AIP is characterized 
by clear clinical, histologic, radiologic, 
and serologic findings, differentiating 
the inflammatory process from 
pancreaticobiliary malignancies 
remains a challenge. Medical therapy 
for AIP consists primarily of short 
(1–2 months) or medium (2–6 months) 
courses of corticosteroids. The use of 
corticosteroids provides an opportunity 
for therapy as well as a diagnostic 
assessment in terms of resolution of 
pancreatic lesions.
In a recent series, the success of 
treatment with corticosteroids was 
defined as resolution of the histologic, 
radiologic, and serologic parameters 
[1]. In this series, a week’s course 
of prednisone 30–40 mg/day was 
followed by daily dose tapering of 2.5–
5.0 mg/week. All patients treated with 
steroid therapy for 1 month showed a 
significant reduction in the pancreatic 
abnormality as defined by the results 
of computed tomography (CT) and 
magnetic resonance imaging (MRI). In 
addition, serum gamma-globulin, IgG, 
and CA19-9 levels returned to normal 
during the course of the corticosteroid 
therapy. The patients were followed for 
a period of between 12 and 142 months 
and there were no indications for 
progression of pancreatic malignancy 
and no recurrence of symptoms of 
jaundice or abdominal pain. A poor 
response to 1–2 weeks of corticosteroid 
therapy should raise concern for the 
possibility of pancreatic cancer or forms 
of non-AIP chronic pancreatitis.
Short-course 
corticosteroids
Hirano et al. have described the 
response to a short course of steroids 
[2]. Nineteen patients diagnosed with 
AIP using the Mayo Clinic criteria 
were treated with a prednisone dose 
of 25–50 mg per day for 2–4 weeks. 
The dose was tapered by 5 mg every 
2–4 weeks until the daily dose reached 
5 mg, followed by maintenance 
therapy at a dose of 2.5–5.0 mg/day. 
In all 19 patients, imaging findings 
and laboratory abnormalities improved 
4 weeks after initiation of steroid 
therapy. In comparing AIP patients 
treated with corticosteroids and to those 
patients not treated, it was found that 
AIP-related unfavorable events such 
as jaundice, abnormal liver function 
tests, and pancreatic pseudocyst were 
reduced in the corticosteroid-treated 
group. During follow-up of the patients 
not treated with corticosteroids, it was 
found that unfavorable events were 
observed in 16 of 23 patients (70%) 
after 25 months on average from onset.
The effectiveness of corticosteroid 
therapy may be due to its role in 
improving bile duct stenosis in patients 
with obstructive jaundice. Using a 
longer course of corticosteroids, Ito 
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*	Mayo	criteria:	Histology:	1,	periductal	lymphoplasmacytic	infiltrate	with	obliterative	phlebitis	and	storiform	fibrosis	or	2,	lymphoplasmacytic	infiltrate	with	storiform	fibrosis	showing	
abundant	(>	10	cells/high-powered	field)	IgG4-positive	cells;	Typical:	diffusely	enlarged	gland	with	delayed	(rim)	enhancement;	diffusely	irregular,	attenuated	main	pancreatic	duct;	Other:	
focal	pancreatic	mass/enlargement;	focal	pancreatic	duct	stricture;	pancreatic	atrophy;	pancreatic	calcification;	or	pancreatitis;	elevated	serum	IgG4	level	(normal,	8–140	mg/dL);	hilar/
intrahepatic	biliary	strictures,	persistent	distal	biliary	strictures,	persistent	distal	biliary	stricture,	parotid/lacrimal	gland	involvement,	mediastinal	lymphadenopathy,	retroperitoneal	fibrosis;	
resolution/marked	improvement	of	pancreatic/extrapancreatic	manifestation	with	steroid	therapy.
†	Japan	Pancreas	Society	criteria:	Typical	imaging:	diffuse	enlargement	of	pancreas	along	with	diffuse	(>	33%)	main	pancreatic	duct	narrowing	with	an	irregular	wall	and	1,	serology:	
autoantibodies,	elevated	gamma-globulins	or	IgG	or	2,	histopathology:	lymphoplasmacytic	infiltrate	and	pancreatic	fibrosis.
‡	Main	pancreatic	duct.
§	Not	indicated	in	paper.
First	author,	ref. Patients	
(n)
Diagnostic	criteria Dose Steroid	therapy	duration Responses	to	
therapy	(n)
Song	[1] 4 1,	diagnostic	histopathologic	features	and	bound	IgG4+	
plasma	cells	on	pancreatic	tissues;	2,	characteristic	imaging	
on	CT	and	pancreatography,	together	with	increased	serum	
IgG,	gamma-globulin	levels	or	presence	of	autoantibodies;	3,	
response	to	steroid	therapy
30–40	mg/d	×	
1	wk
Taper	daily	dose	by	2.5–5	mg/wk 4
Hirano	[2],	
Nishimori	[16]	
19 Mayo	* 25–50	mg/d	×	
2–4	wk
Taper	5	mg	every	2–4	wk	until	
5	mg/d,	then	2.5–5.0	mg/d	for	
maintenance
19
Ito	[8] 14 JPS	† 30,	40	mg/d	×	
2	wk
Taper	over	2–3	months 98.4%	remis-
sion	rate
Kamisawa	[7] 10 Enlargement	of	the	pancreas,	irregular	narrowing	of	the	
MPD,‡	hypergammaglobulinemia	(over	2.0	g/dL),	elevated	
serum	(IgG4,	over	135	mg/dL),	presence	of	autoantibod-
ies,	and	lymphoplasmacytic	infiltration	with	fibrosis	of	the	
pancreas
30–40	mg/d Taper	by	5	mg	every	1–2	wk 10
Okazaki	[17]	 21 JPS NI	§ NI NI
Kubota	[4]	 12 JPS 30	mg/d	×	2	wk Taper	by	5	mg/wk	until	daily	
does	of	5	mg	reached
12
Church	[6] 11 1,	increased	levels	of	serum	gammaglobulin	or	IgG4;	2,	
presence	of	autoantibodies;	3,	diffuse	enlargement	of	the	
pancreas	or	a	pancreatic	mass;	4,	diffuse	irregular	narrowing	
of	the	MPD;	5,	fibrotic	changes	with	lymphocyte	infiltration;	6,	
no	symptoms	or	only	mild	symptoms,	usually	without	attacks	
of	acute	pancreatitis;	7,	rare	pancreatic	calcification	or	cysts;	
8,	occasional	association	with	other	autoimmune	diseases;	
9,	effective	steroid	therapy
30	mg/d Tapered	over	2–3	months 11
Kamisawa	[18]	 10 Swelling	of	the	pancreas,	irregular	narrowing	of	the	MPD,	
hypergammaglobulinemia,	elevation	of	serum	IgG4,	pres-
ence	of	autoantibodies,	association	with	other	autoimmune	
diseases,	and	lymphoplasmacytic	infiltration	with	fibrosis
5,	30,	40,	60	mg/d Tapered	by	2.5–5	mg	every	
1–2	wk
10
Ito	[3] 3 Hypergammaglobulinemia,	eosinophilia,	US	showing	hy-
poechoic	diffuse	swelling	of	pancreas,	ERCP	showing	diffuse	
narrowing	of	the	MPD	with	irregular	thumbprint-like	marks,	
reversible	exocrine	insufficiency,	and	positive	anticarbonic	
anhydrase	II	antibody	
30	mg/d 1	month 3
Chari	[9] 17 Mayo 40	mg/d	×	4	wk Tapered	by	5	mg	/wk	over	8	wk 17
Moon	[10]	 22 Previously	reported	“cardinal	features	of	AIP”	and	one	of	
following	imaging	features:	1,	diffuse	pancreatic	enlargement	
with	or	without	capsule-like	rim;	2,	delayed	enhancement	of	
pancreatic	mass;	3,	diffusely	attenuated	MPD	with	irregular	
wall;	4,	none-to-mild	upstream	duct	dilation	despite	long	
stricture;	5,	double	duct	sign	without	a	pancreatic	mass	in	
a	patient	with	obstructive	jaundice;	6,	association	of	hilar	or	
intrahepatic	duct	strictures;	or	7,	other	organ	involvement	
unusual	for	pancreatic	cancer	such	as	a	salivary	gland,	
kidney,	or	retroperitoneal	fibrosis
0.5	mg/kg/d	×	
1–2	months
Tapered	by	5–10	mg/month	to	
dose	of	2.5–7.5	mg/d
15
Ghazale	[11] 30 Mayo 40	mg/d	×	4	wk Tapered	by	5	mg/wk	for	total	
of	11	wk
29
Table 1. Response of patients with autoimmune pancreatitis (AIP) to steroid 
therapy. All studies included in the table are sources of primary data.
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et al. described the course of 125 
patients diagnosed with AIP as defined 
by the Japanese Pancreas Society 
(JPS) criteria [3]. The patients were 
started on a prednisone dose of 30 mg 
or 40 mg for 2 weeks and tapered 
over 2–3 months, leading to a 98.4% 
remission rate (123 of 125). The 
authors found that patients who had 
corticosteroid therapy took 89.7 days on 
average to reach complete remission, 
whereas those patients without 
corticosteroid therapy took 149.8 days 
to reach complete remission. It is 
important to note that untreated 
patients demonstrated a high rate of 
spontaneous remission.
With increasing experience with 
the initial corticosteroid therapy, it has 
become apparent that short courses 
might be as effective as a moderate 
course of corticosteroids. In the series 
by Kubota et al., 12 patients were 
diagnosed with AIP using the JPS 
criteria and started on 30 mg/day for 
2 weeks [4]. The dose was tapered 
by 5 mg per week until a daily dose 
of 5 mg was reached. All 12 patients 
showed a complete response to steroid 
therapy.
The pace of corticosteroid tapering 
in the initial therapy of AIP has been 
described by Kamisawa et al. [5]. Ten 
patients were diagnosed with AIP using 
the following criteria: enlargement 
of the pancreas, irregular narrowing 
of the main pancreatic duct (MPD), 
hypergammaglobulinemia (over 2 g/
dL), presence of autoantibodies, and 
lymphoplasmacytic infiltration with 
fibrosis of the pancreas. All 10 patients 
were started on 30–40 mg/day of 
prednisone, and the dose was tapered 
by 5 mg every 1–2 weeks. Steroid 
therapy was effective morphologically 
and serologically in all 10 patients with 
AIP. Pancreatic enlargement showed 
improvement from 1 to 2 weeks after 
initiation of treatment, and the pancreas 
returned to normal size within 3–
4 weeks after the start of therapy.
Symptom response to 
corticosteroids
The symptoms of AIP, including 
jaundice will also resolve with 
corticosteroid therapy [6]. Eleven 
patients were started on a corticosteroid 
dose of 30 mg per day, which was 
tapered over 2–3 months, and in all 
patients there was an improvement of 
symptoms within 4 weeks. Jaundice 
and abdominal pain were eliminated 
over the course of treatment. 
Improvement in serologic values also 
improved with the symptoms.
A number of radiologic and serologic 
criteria can be used to monitor response 
to therapy. Kamisawa et al. tracked the 
serologic, morphologic, and imaging 
response to corticosteroids [7]. Ten 
patients diagnosed with the criteria 
indicated in Table 1 were started on 
initial prednisone doses of 5, 30, 40, or 
6 mg per day. The doses were tapered 
by 2.5–5.0 mg every 1–2 weeks, and all 
10 patients improved clinically as well as 
with objective criteria. In a small series of 
patients, Ito et al. have demonstrated the 
response to prednisone 30 mg/day [8]. 
Three patients were treated with 30 mg/
day for 1 month, and all responded 
to treatment as defined by clinical 
symptoms and radiologic changes. Since 
the pancreas can sometimes undergo 
marked atrophy after corticosteroid 
therapy, the authors suggest that 
steroids should be discontinued after 
adequate morphological improvement.
The pancreatic manifestations of AIP 
should be responsive to corticosteroid 
therapy. In the study by Chari et al., 
17 AIP patients were followed for a 
period of between 2 and 56 months, 
and all patients showed complete 
resolution of pancreatic manifestations 
Table 2. Response of 
patients with autoimmune 
pancreatitis (AIP) treated 
with surgical resection.
First author, 
ref.
Patients (n) Type of surgical resection n Response to therapy (n)
Song [1] 21/43 Pancreaticoduodenectomy 4 All resections done in 
this study for suspected 
pancreatic malignancy
Choledochojejunostomy 14
Radiofrequency ablation of pancreatic 
head
1
Intraoperative biopsy of pancreatic tis-
sues
2
Ito [3] 2/21 Pancreatic resection 2
Toomey [12] 2 Diagnostic laparoscopy with choledocho-
jejunostomy 
1 1
Diagnostic laparoscopy with biopsies and 
subsequent steroid therapy
1 1
Kamisawa [7] 10 Pancreatoduodenectomy 6 6
Choledochojejunostomy 4 4
Hardacre [13] 37 Pancreaticoduodenectomy 37 68% improved (subjec-
tive)
Weber [14] 29 Pancreaticoduodenectomy 23 8/29 developed recur-
rence of symptomsDistal pancreatectomy 4
Total pancreatectomy 2
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[9]. The authors also demonstrated that 
bile duct strictures are responsive to 
corticosteroid therapy. Of the 17 patients, 
three had intrahepatic biliary strictures 
and five had obstructive jaundice with 
distal biliary strictures. All eight of these 
patients showed marked improvement 
and resolution of biliary manifestations, 
with a normal biliary tree and pancreatic 
duct on follow-up imaging.
Diagnostic course of steroids
A course of corticosteroids is used 
primarily to provide therapy, but 
corticosteroids can also be used 
diagnostically. Moon et al. showed that 
in 22 patients diagnosed with AIP using 
a blend of criteria, 15 responded to 
steroids, whereas the seven patients 
who did not respond were found to 
have pancreatic cancer [10]. All 22 
patients were treated with an initial 
dose of prednisone (0.5 mg/kg/day) 
for 2 weeks. A positive response to 
steroids was defined by complete 
resolution or significant improvement 
of MPD narrowing and resolution, 
or a significant reduction of the 
pancreatic mass. A negative response 
to corticosteroids was defined as a 
lack of improvement of MPD narrowing 
and no resolution or reduction of the 
pancreatic mass. In the 15 patients who 
responded favorably to corticosteroids, 
there was complete resolution, as 
demonstrated by symptomatic, 
radiologic, and serologic improvement. 
This remission was achieved with a 
regimen of prednisone 0.5 mg/kg/
day for 1–2 months, followed by a 
gradual taper of 5–10 mg/month to a 
maintenance dose of 2.5–7.5 mg/day, 
which was continued for an average of 
6 months. In the other group, those who 
had a “negative steroid response,” all 
seven patients showed narrowing of the 
MPD and enlargement of the pancreas 
with disease progression. The study by 
Moon et al. clearly shows the value of 
a short-duration trial of steroid therapy 
in assessing for steroid responsiveness 
in suspected AIP patients. The 2-week 
duration of steroids used in this trial did 
not appear to have a negative impact 
on those patients with pancreatic 
malignancy. It is important to note 
that this diagnostic trial should be 
reserved for patients who have had an 
extensive evaluation for the possibility 
of malignancy, including a pancreatic 
biopsy or aspiration cytology.
Finally, Ghazale et al. investigated 
the response of strictures to 
corticosteroid therapy [11]. In this series 
of 30 patients diagnosed with AIP using 
the Mayo criteria, the patients were 
treated with 40 mg/day prednisone for 
4 weeks. The dose was tapered by 
5 mg per week for a total of 11 weeks 
of treatment. Twenty-nine of the 30 
patients responded to corticosteroids. 
One patient remained refractory to 
steroids and required prolonged 
biliary stenting. Liver enzyme levels 
normalized in 61% of the 30 patients.
Surgical management of AIP
Autoimmune pancreatitis (AIP) can 
be very difficult to distinguish from a 
focal malignancy such as pancreatic 
adenocarcinoma, as the clinical 
presentation and radiologic findings can 
be very similar. The lingering suspicion 
of an occult malignancy often stimulates 
clinicians to pursue further diagnostic 
testing. Although a careful evaluation 
before and after steroid therapy 
provides additional evidence of a 
malignant or a benign process, surgical 
therapy and a pancreatic resection are 
at times indicated.
In a series of 43 patients with a 
presumptive diagnosis of AIP, Song et 
al. found that a significant percentage 
of patients required a diagnostic 
surgical exploration [1]. Twenty-
one of the 43 patients diagnosed 
with AIP underwent exploratory 
laparotomy due to the possibility of 
a misdiagnosed pancreaticobiliary 
malignancy. Unfortunately, pancreatic 
biopsy or fine-needle aspiration 
(FNA) may provide false-negative 
results in terms of malignancy. 
Clinical manifestations and radiologic, 
histologic, and serologic evidence 
are therefore used to detect clues for 
a diagnosis of an occult pancreatic 
malignancy. Toomey et al. described 
two cases of AIP in which one patient 
underwent a diagnostic laparoscopy 
with choledochojejunostomy and 
the other underwent a diagnostic 
laparoscopy with intraoperative biopsies 
and subsequent steroid therapy [12]. 
The indications for surgical exploration 
were met after failure to satisfy all 
diagnostic criteria, coupled with a 
suspicion of malignancy. Both patients 
did well postoperatively and did not 
have a relapse of their AIP. Kamisawa 
et al. followed six patients who 
underwent pancreatoduodenectomy 
and four patients who underwent 
choledochoduodenostomy [7]. All 
patients in both groups showed 
improvement of their jaundice. One 
patient in the pancreatoduodenectomy 
group progressed to Sjögren syndrome, 
with swelling of the cervical lymph 
nodes, and underwent corticosteroid 
therapy. Another patient in the 
choledochoduodenostomy group 
developed hydronephrosis, probably 
due to associated retroperitoneal 
fibrosis, and subsequently underwent 
steroid therapy.
The surgical approach to AIP 
includes resection for diagnostic 
considerations as well as for therapy. In 
a study by Hardacre et al., 37 patients 
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First author, ref. n Alternative medical therapy Response to therapy (n)
Church [6] 6 Azathioprine 1–2 mg/kg/d 4
Topazian [15] 1 Rituximab 375 mg/m2 weekly for 
four doses
1
Table 3. Response of patients with autoimmune pancreatitis (AIP) patients treated 
with alternative medical therapy
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with AIP (termed “lymphoplasmacytic 
sclerosing pancreatitis,” LPSP) 
underwent pancreaticoduodenectomy 
for suspicion of malignant disease [13]. 
Postoperatively, none of the patients 
was noted to have recurrent jaundice. 
One patient in the group suffered from 
recurrent episodes of acute pancreatitis, 
manifested by abdominal pain and 
elevated serum amylase and lipase 
levels. In a study by Weber et al., 29 
patients diagnosed with AIP (referred to 
as LPSP) were found to be candidates 
for curative resection of the pancreas. 
Of the 29 patients, almost one-third 
(eight of 29) developed a recurrence of 
symptoms, with seven showing jaundice 
and one with recurrent pancreatitis [14]. 
It is important to note that the seven 
patients with recurrent jaundice were 
found to have biliary stricturing at the 
time of direct cholangiography. All 29 
patients were confirmed as having AIP 
by pathologic classification, and there 
were no signs of malignancy.
Noncorticosteroid therapy
Comparisons of maintenance 
corticosteroid treatment with the use 
of immunomodulatory drugs have 
not been well investigated. Cases 
have been reported sporadically, with 
varying responses to treatment. It is 
important to realize that as with low-
dose steroids, immunomodulatory 
drugs such as azathioprine and 
mycophenolate mofetil have their own 
side effects. Church et al. described 
a series of 11 patients diagnosed with 
AIP who were treated with prednisolone 
therapy over a 2–3-month period [6]. 
During an 18-month follow-up, six of 
the 11 patients relapsed on reduction 
of the steroid dose, at which point 
the prednisolone dose was increased 
and azathioprine 1–2 mg/kg/day 
was initiated. Four of the six patients 
(one patient declined azathioprine) 
improved on the combined steroid 
and azathioprine treatment. Ghazale 
et al. also reported that recurrence 
of disease-related symptoms was 
associated with biochemical and/
or serologic relapse in 16 of 30 
corticosteroid-treated AIP patients 
(53%) [11]. Six of the 16 patients were 
treated with either azathioprine (initially 
50 mg/day, increased 2.0–2.5 mg/
kg), mycophenolate mofetil (500 mg 
twice daily, increased to 750 mg twice 
daily) or cyclophosphamide (Cytoxan). 
The six patients were subsequently 
maintained in remission on these 
medications, without any further 
relapses after a median follow-up 
period of 6 months.
Topazian et al. recently documented 
the use of new immunomodulatory 
agent in a case report in which medical 
therapy with the monoclonal antibody 
rituximab produced a promising 
response [15]. The patient in this 
case report had immunoglobulin 
G–associated cholangitis (IAC), an 
entity with many features in common 
with AIP. The patient was treated with 
an 8-week tapering course of oral 
prednisone, starting with 50 mg/day. 
The patient had recurrent abdominal 
pain and was re-treated with a 12-
week course of prednisone. His course 
was complicated by recurrent biliary 
strictures requiring biliary stenting 
and another course of corticosteroids. 
The biliary strictures persisted, and 
the patient received another 12-
week course of prednisone along 
with 6-mercaptopurine at a dose of 
1.5 mg/kg/day for 8 months. After 
cholangiography and endosonography 
of the pancreas, a diagnosis of AIP and 
IAC with ocular involvement refractory 
to prednisone and 6-mercaptopurine 
was made. Therapy with rituximab 
at 375 mg/m2 weekly for four doses 
was initiated, primarily for therapy 
of the ocular disease. After 1 month 
of therapy, the patient began to 
notice improvement in his vision, his 
symptoms of jaundice and steatorrhea 
were relieved, and maintenance 
rituximab 375 mg/m2 (every 3 months) 
was started. Four months after 
rituximab was initiated, endoscopic 
retrograde cholangiopancreatography 
(ERCP) showed improvement in 
the biliary strictures and allowed 
for removal of the biliary stents. 
The efficacy of rituximab has been 
documented in inflammatory diseases 
such as rheumatoid arthritis. However, 
data with regard to duration and 
maintenance therapy have not been 
reported. Although the report by 
Topazian et al. [15] involved only one 
patient, the dramatic response to 
therapy has raised the possibility of 
rituximab providing an alternative to 
Imuran and 6-mercaptopurine. 
Summary
The radiologic, clinical, and serologic 
findings associated with AIP are highly 
responsive to medical therapy. The 
vast majority of patients respond 
to a 1-month course of moderate 
doses of corticosteroids followed 
by low-dose corticosteroid therapy. 
Alternatives to corticosteroid therapy 
include immunosuppressants such as 
azathioprine. Patients not responding 
appropriately to medical therapy 
should be considered for surgical 
confirmation of AIP.
Fig 1. Endoscopic retrograde 
pancreatography (ERP) before (a) 
and after (b) 1 month of moderate-
dose corticosteroids.
A
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TTT Trial Design Workshop
The first Trial Design Workshop was 
held in Dubrovnik in Croatia on 1–2 
April. A survey of alumni at previous 
TTT courses had suggested that 
participants would welcome an 
extension of the “Trial Design” module. 
Professor Stimac of the Croatian 
Gastroenterology Society, a TTT 
faculty member, took up the challenge 
in conjunction with the TTT Committee, 
and a 2-day workshop with a small 
number of participants was planned.
Twenty-two people enrolled, 
representing eleven different 
countries. A faculty of seven from 
six different countries made up the 
rest of the group. The workshop was 
run with the now-familiar TTT format 
of lectures followed by small-group 
work and discussions conducted by 
the participants. In addition to the 
main topics covered (see box), the 
WGO Research Committee provided 
extensive references and materials for 
researchers to use in preparing and 
conducting their own clinical research.
As is the tradition at TTT meetings, 
social activities were included 
alongside the course. It’s during these 
activities that friendships are made 
and potential future collaborations in 
research and other gastroenterology-
related activities develop.
In general, evaluations of the 
course both by participants and by 
faculty members showed it had been 
a very successful new venture for 
WGO and effective in what it tried to 
achieve. Of course, only the future will 
show whether the event will lead to 
successful research by the members 
of the group. As coordinator of the 
workshop, I am particularly grateful to 
the dedicated faculty members for all 
the work that was done both before 
and during the meeting. I am also 
grateful to our Croatian hosts, who 
had the vision to see the importance 
of this type of event in enhancing our 
specialty. Finally, without the support 
of Medconnect and Tatjiana Jurcic and 
her colleagues, the course would not 
have been possible.
We in WGO look forward to 
repeating the Trial Design Workshop 
in other parts of the world and in 
conjunction with other national 
societies. This type of workshop 
would work well in conjunction with 
a major national society meeting, 
and we believe it could help enhance 
the quality of the overall meeting by 
providing a focused experience in a 
particular subject. Other topics that 
have been highlighted by TTT alumni 
as possible topics for future workshops 
include procedural skills training, 
assessment, and appraisal and 
credentialing.
1–2 April 2009 (Dubrovnik, Croatia)
Topics at the TTT Trial Design Workshop
•  Asking the question
•  Logistics—planning a study
•  Ethics and the institutional review board
•  Choosing the best trial design
•  Data collection, interpretation, statistics, analysis
•  Successful grant writing
Participants and faculty gathered in the foyer of the Palace 
Hotel, Dubrovnik (the venue for the workshop).
Jim Toouli, MD
WGO Coordinator for Education and Training 
Professor of Surgery, Flinders University, 
Adelaide, Australia
The World Gastroenterology 
Organisation (WGO) and the American 
College of Gastroenterology (ACG) 
have agreed to a joint collaboration 
in which the organizations agreed to 
work in concert on a variety of key 
educational initiatives both in the U.S. 
and around the world. The goal of 
this partnership is to build upon the 
unique strengths and capacities of 
each organization to create synergies 
that promise to expand and enhance 
education for gastroenterologists 
worldwide. The initial agreement, which 
will last for a period of 5 years, covers 
a number of important educational 
programs, while opening the door to 
further collaboration on multiple fronts.
WGO’s global reach and expertise 
combined with ACG’s leading voice 
in clinical gastroenterology make this 
partnership a wonderful opportunity 
to expand and improve clinical 
gastroenterology practice and training 
around the world.
Train the Trainers
ACG shares WGO’s commitment to 
the “Train the Trainers” (TTT) program 
and its approach to providing clinician 
educators with the skills needed 
to teach adult learners effectively. 
During the past several years, 
the ACG has become a frequent 
participant in TTT meetings across 
the world by sponsoring attendees. 
After participating in a number of 
programs as attendees, a number of 
ACG leaders have taken on the role of 
TTT faculty at subsequent meetings. 
The reports from the meetings have 
been uniformly outstanding, showing 
TTT to be a unique and important 
training opportunity for those teaching 
the future leaders and practitioners in 
clinical gastroenterology. ACG pursued 
these interests even further by hosting 
a TTT program in southern Florida 
in September of 2008; this was an 
outstanding success. It was after acting 
as a host society itself that the ACG 
gained a true appreciation for this one-
of-a-kind international training program.
The impact these programs have 
on clinical gastroenterology across 
the globe is deeply appreciated by 
the ACG. As a result, ACG wanted 
to explore ways of supporting 
future TTTs. During the term of the 
agreement, ACG will therefore provide 
annual financial support for the Train-
the-Trainers programs as well as 
support for ACG faculty and attendees. 
The ACG will be recognized as a major 
sponsor of TTT with the WGO and will 
be recognized at each event as well as 
in promotional activities.
In addition to sponsoring future 
TTT meetings, the ACG will also have 
the ability to tap into the outstanding 
teaching and evaluation materials that 
have been developed for the program. 
It is the hope of both organizations that 
these materials can be expanded and 
applied to various types of programming 
in the U.S. that meet the specific and 
unique needs of the U.S. health care in 
training modules. An additional area of 
exploration includes developing a TTT 
style program appropriate for regular 
use with academic clinicians in the U.S. 
The WGO will obtain access to the data 
from any ACG-sponsored programming 
in the U.S., using the TTT or related 
materials for outcomes studies that may 
be produced.
World Digestive 
Health Day Partners
Another area of collaboration is in the 
annual World Digestive Health Day. 
The ACG will partner with the WGO 
to develop education and awareness 
programs in the United States based 
on the topics selected by the WGO. 
These activities will begin this year with 
the topic of irritable bowel syndrome 
(IBS) and will continue in future years 
as well. Through joint efforts involving 
media and strategic communications, 
both groups will maximize their potential 
to deliver important health messages 
to patients on IBS and digestive health 
generally will be maximized.
International Training Centers
Through this collaboration agreement, 
the ACG and WGO have also pledged 
to explore opportunities to work 
together in support of the WGO’s 
initiative to develop and support training 
centers around the world. Among the 
possible areas for collaboration are 
sponsoring trainee scholarships to 
support travel to the centers; supporting 
educational programs at the centers; 
providing faculty and teaching materials 
to the centers; and assisting with 
networking opportunities amongst the 
existing centers.
The ACG and WGO very much 
look forward to this new phase in 
their long-standing partnership 
and expect that the benefits of 
working together on issues critical 
to the future advancement of clinical 
gastroenterology and improving patient 
outcomes will flow across the United 
States and the entire world. The ACG 
recognizes the important contribution 
made by Dr. Eamonn Quigley to the 
cultivation of this opportunity to partner 
with WGO. As current President of the 
College, and in light of his role in WGO, 
Dr. Quigley is well-positioned to see 
the tremendous potential for successful 
collaboration from the points of view 
of both organizations and also to 
represent their mutual interests.
WGO and ACG Global  
Collaboration Agreement
Amy Foxx-Orenstein, MD
Immediate Past President, American College of Gastroenterology  
Division of Gastroenterology and Hepatology, Department of  
Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester,  
MN 55905, USA. 
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The WGO co-sponsored a gastrointestinal endoscopy workshop at the 
Korle Bu Teaching Hospital in Accra, Ghana, from 29 September to 
2 October 2008. The workshop, which was also sponsored by the Mayo 
Clinic and by the Korle Bu Medical Center, was designed to provide 
instruction in colonoscopy to reach the cecum and in endoscopic therapy 
for gastrointestinal bleeding. The 14 attendees from Ghana, Côte D’Ivoire, 
and Nigeria included novices and experienced endoscopists.
The course was held in an ex-vivo laboratory featuring synthetic, 
porcine, and bovine endoscopy models, and also clinical procedures 
were also attended along with faculty. Over the 4 days of the course, the 
attendees improved their colonoscopy skills and many performed their 
first variceal band ligation procedures. Some attendees also learned 
esophageal dilation and stent placement techniques.
The WGO was represented by Dr. Eamonn Quigley and Dr. Damon 
Bizos; other faculty included Dr. Rudolph Darko (of the Korle Bu 
Department of Surgery) and doctors Joseph Kolars, Lewis Roberts, 
Robert Sedlack, and Mark Topazian of the Mayo Clinic, Rochester, 
Minnesota. Endoscopy equipment and accessories were provided by 
Olympus KeyMed, Karl Storz Endoscopy, and Cook Medical. The aid 
organization International Aid (Spring Lake, Michigan) provided laboratory 
and teaching space in the Korle Bu Surgical Skills Training Center.
Endoscopy workshop in Ghana
Mark Topazian, MD
Division of Gastroenterology and Hepatology, 
Mayo Clinic, 200 First Street SW, Rochester, 
MN 55905, USA.
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Dr. Quigley leads a lunchtime discussion.
Course attendees in front of the Korle Bu 
Surgical Skills Training Center.
Dr. Sedlack teaches colonoscopy in the 
ex-vivo laboratory.
World Digestive 
Health Day
May 29, 2009
Irritable Bowel 
Syndrome
IBS: The Hidden Disease 
700 million people worldwide are affected  
by irritable bowel syndrome but yet 90% of  
IBS sufferers do not seek medical care.
It is now recognized that Irritable Bowel Syndrome (IBS) is a truly global problem reportedly affecting 
millions of individuals worldwide and exerting a significant influence on the quality of life both for the many 
reported and unreported cases. Yet, despite volumes of research highlighting the prevalence and impact of 
IBS worldwide, IBS remains poorly understood by the medical community and the general public alike.
WGO recognises therefore, that there exists a very significant “knowledge gap” with regard to all aspects of 
IBS and there is a real unmet need to bring the very latest information on IBS to medical practitioners, other 
health care workers and the general public. For this reason, WGO, in partnership with industry sponsors, 
focuses the attention of the global gastroenterology community on May 29, 2009 on IBS.
As many as 65% of 
children with frequent 
abdominal pain 
actually have irritable 
bowel syndrome
Sufferers report a 
staggering 34% loss of 
overall work productivity 
– equivalent to almost 
14 hours per week
90% of people who 
suffer from long-term 
symptoms do not seek 
medical advice and  
are left undiagnosed
WDHD is a program of WGO
World Gastroenterology Organisation
 
http://www.worldgastroenterology.org/wdhd-2009.html
Did You
Know 
That
World Digestive Health Day: 
May 29, 2009
Irritable Bowel Syndrome 
WGO calls upon all members of the 
global gastroenterology community to 
raise awareness about IBS amongst their 
colleagues, patients and staff.  
IBS Tools
WGO has put together a collection of tools 
to help you raise awareness about IBS.  
 
Tools for Doctors: 
IBS Guideline
Test for diagnosing IBS
Questions patients ask about IBS
Review of the best articles published 
about IBS, our “Monthly Research 
Review” service
Do you have patients who need more 
information about digestive health?  
WGO has put together tools to help you 
address these needs. 
Tools for Patients: 
Edu-lessons about digestive health
Online test to help patients evaluate 
and improve their digestive health
Access the tools online: 
http://www.worldgastroenterology.org/wdhd-2009.html
http://www.wgofoundation.org/wdhd-2009.html
•
•
•
•
•
•
WDHD EvEnts arounD tHE WorlD takE 
placE on six continEnts:
HigHligHts of WorlD DigEstivE HEaltH Day
 
Toowoomba, Australia: May 25-29  
World Gastroenterology Awareness week
Pune, India: May 29  
An IBS-awareness campaign for the general public and the medical 
Fraternity. Related to the website www.ibspune.net  
Darfur, Sudan: May 28-29  
IBS Symposium
Kiev, Ukraine: May 29  
World Digestive Health Day Conference for health care professionals
Cincinnati, USA:  
WGO Summit Task Force opens with a meeting on “A Global 
Perspective on IBS”
Caracas, Maracaibo and Barquisimeto in Venezuela: May 29  
Street events, speeches, infomercials and discussions on World 
Digestive Health Day   
Iran: May 21-29  
A series of seminars, radio and TV programs will take place during 
the World Digestive Health Week
17. Pakistan: Peshawar
18. Pakistan: Lahore 
19. Saudi Arabia: Kauh
20. Saudi Arabia: Riyadh
21. Slovakia: Bratislava
22. South Africa: Johannesburg
19. Durban, Cape Town
23. Spain: Granada
24. Sudan: Khartoum
25. Ukraine: Kyiv
26. United Arab Emirates: Abu Dhabi
27. Uruguay: Montevideo
28. USA: Cincinnati
29. Venezuela: Caracas,  
27. Maracaibo, Barquisimeto
30. Yemen: Sana’a
1. Argentina: La Plata
2. Argentina: Mar del Plata
3. Australia: Toowoomba
4. Belarus: Minsk 
5. Chile: Santiago de Chile
6. Greece: Athens
7. Guatemala
8. India: Bhubaneswar
9. India: Pune
10. Indonesia: Jakarta
11. Iran
12. Jordan: Amman
13. Malaysia: Selangor
14. Mexico: Mexico DF
15. Nepal: Dharan
16. Nicaragua: Managua
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In the past few years, there has been 
considerable interest in irritable bowel 
syndrome (IBS) in Mexico, possibly 
due to the development of the Rome 
criteria. There has been an increase 
in the number of studies on the topic 
presented annually at the Mexican 
National Gastroenterology Week and in 
the number of reports on it in the Revista 
de Gastroenterología de México (the 
Mexican gastroenterology journal) and 
other international publications.
Epidemiological data
Recent studies have led to a better 
understanding of the epidemiology 
of IBS in Mexico. In a community-
based study using the Rome II criteria, 
conducted in the state of Tlaxcala in 
central Mexico, IBS was found to have 
a prevalence of 16% [1]. By contrast, in 
another study among volunteers from 
a university population in the south 
of Mexico City, the frequency of IBS 
was 35% [2]. Between 70% and 80% 
of those who met the criteria for IBS 
were female. In these studies, IBS-
C (constipation-predominant) was 
more frequent than IBS-D (diarrhea-
predominant) [1,2]. More recently, in 
a study that included more than 2400 
private-practice patients nationwide, 
using the Rome III criteria, 49% were 
classified as having IBS-M (mixed), 42% 
as having IBS-C, 6% as having IBS-D 
and 3% as having IBS-U (unsubtyped) 
[3]. The higher frequency of constipation-
predominant IBS in comparison with the 
diarrhea-predominant form has been 
confirmed in an international study that 
compared symptoms in eight countries 
(USA, Mexico, Canada, England, Italy, 
Israel, India and China) [4].
In Mexico, IBS is the first reason 
for consulting a gastroenterologist 
in approximately 23% of cases. The 
main reasons patients consult are 
pain/abdominal discomfort, symptoms 
brought on by stress, impairment of 
everyday activities, and (in a smaller 
proportion) fear of cancer [5]. However, 
bloating and abdominal distension 
are considered the most bothersome 
symptoms. In fact, Mexican patients 
report higher bloating scores in 
comparison with patients in other 
countries [4]. We have also observed 
that patients aged 30–50 who seek 
medical attention report pain and 
abdominal bloating during the previous 
week significantly more intense than 
that reported by patients younger than 
30 and older than 50. This may explain 
the higher rate of consultation for IBS 
symptoms during the fourth decade  
of life [6].
Patients in Mexico also consulted 
three or four times per year, in 
comparison with non-IBS patients who 
do so only about twice a year, and 
they seek medical attention for both 
gastrointestinal and nongastrointestinal 
symptoms, leading to a high rate of 
unnecessary diagnostic testing [7]. Even 
after IBS has been diagnosed using the 
accepted criteria, excessive numbers of 
diagnostic evaluations are still ordered. 
It has been shown that if minimum work-
up is done, as recommended by the 
various guidelines available such as 
the Latin American Consensus on IBS, 
there would be considerable economic 
savings (66% and 95%) [8]. Another 
point that stands out is the high rate of 
abdominal surgery in our patients. For 
example, appendectomies are 16 times 
more likely and cholecystectomies are 
2.5 times more frequent among IBS 
patients than in those discharged after 
treatment for other conditions [7]. In our 
experience, one of the reasons for the 
excess of consultations is the lack of an 
effective treatment for IBS. It could also 
be due to the lack of information and 
reassurance provided by physicians. 
In fact, we have proved that the 
simple intervention of providing better 
information can acutely modify patients’ 
perception of their degree of impairment 
in daily life [5].
Health-related quality 
of life (HRQOL)
It is known that IBS patients’ quality of 
life is reduced in comparison with the 
general population, at a rate similar to 
that patients with chronic renal failure 
or those with liver problems due to 
hepatitis C. In addition, the impact of 
IBS on the HRQOL in female patients 
is greater than that reported by female 
patients in other countries with regard to 
body image, concern about health, and 
interference with everyday activities [9]. 
Some factors, such as fear of cancer, 
impairment of everyday activities, 
and symptom-related stress may also 
influence the HRQOL [5].
Postinfectious IBS and 
other comorbidities
There are insufficient data about the 
frequency of postinfectious IBS in 
Mexico. A small retrospective study 
reported a frequency of less than 6% 
[10]. However, it is known that among 
American students who visit Mexico 
for short periods, all of those who 
developed IBS after returning home had 
had traveler’s diarrhea, in comparison 
with only half of those who did not 
develop IBS [11].
In relation to other comorbidities, up to 
48% of patients who meet the criteria for 
IBS report heartburn, and more than half 
report symptoms of dyspepsia [12]. In 
addition, 70% of patients have anxiety, 
46% have depression, and 40% have 
both. These findings are associated with 
a larger number of days with abdominal 
pain/discomfort per week and the 
perception of having a more severe 
disease [13]. Fibromyalgia is much 
Max Schmulson, MD
Laboratorio de Hígado, Páncreas y Motilidad (HIPAM),  
Departamento de Medicina Experimental, Facultad de Medicina, 
Universidad Nacional Autónoma de México / Hospital General  
de México, Dr. Balmis #148. Col. Doctores C.P.06726, Mexico
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about IBS in Mexico?
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less frequent than has been reported 
in other countries; however, the overall 
prevalence of fibromyalgia appears to be 
lower in Mexico [14].
Beliefs about IBS in Mexico
As part of a cross-cultural study that 
is in progress, we have informally 
interviewed IBS patients, their relatives, 
and health professionals, and have 
found that IBS is perceived in Mexico 
not as an illness, but as a problem of 
“psychosomatic origin” exacerbated 
by factors involved in food and family 
relationships [15]. Despite this, there is 
considerable resistance to consulting 
a psychotherapist and to the use of 
antidepressants, as the disease might 
then be viewed as a mental illness or a 
form of “madness.” There is a common 
belief that IBS is more frequent among 
women, because they are more “open 
to discussing the subject,” while men 
are more “ashamed” of suffering these 
symptoms and therefore joke about 
it. The patients’ reference to family 
factors represents an ingrained cultural 
factor in which the individual is seen 
as part of a family unit, with personal 
health being affected by interpersonal 
relationships, consistent with previous 
findings in IBS [15]. Also, the lack of an 
effective treatment leads some patients 
to seek treatment with alternative or 
complementary medicine. A study from 
San Luis Potosi has reported that half 
of the patients used these treatments, in 
which herbal preparations are the most 
commonly used agents [16].
The Future
Research is now being conducted 
in Mexico to investigate genetic 
associations in IBS, the translation and 
validation of the more recent Rome 
III criteria, and studies to evaluate 
treatments that are commonly used but 
have not been investigated (at least 
according to the currently accepted 
guidelines for clinical studies in 
functional gastrointestinal disorders). 
Considerable efforts are being made to 
educate health-care professionals about 
the latest concepts of diagnosis and 
treatment of IBS.
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Although there is more that we need to 
learn more about the etiology of IBS, this 
should not keep us from providing nearly 
half of our patients with optimal care. 
Clinical guidelines set high standards 
for the diagnosis and treatment of 
IBS. This review aims to provide 
gastroenterologists with an update on 
some key elements and challenges.
Optimal management of IBS— 
why bother?
IBS is the most common gastrointestinal 
disorder in the population, both in 
primary care and in specialist health 
care. Although not all patients will 
consult for IBS and most consulters 
are handled by family practitioners, 
patients with IBS constitute 30–50% 
of the workload at gastroenterology 
outpatient clinics [1]. The subset who 
are referred to gastroenterologists 
represents only the “tip of the iceberg” of 
IBS, characterized by more pronounced 
symptom intensity and higher levels of 
psychosocial problems than patients in 
primary care [2]. IBS is also associated 
with a markedly reduced quality of 
life and high utilization of health-care 
resources [1,3].
Irritable bowel syndrome (IBS) is 
an enigma. The Rome III Committee 
defines IBS as a functional 
gastrointestinal disorder: symptoms of 
IBS represent the clinical product of 
altered gut physiology and psychosocial 
factors interacting via the brain–gut 
axis. Research on IBS is flourishing, 
with the annual number of publications 
in PubMed exceeding 500 in 2005. 
In particular, research on the basic 
pathophysiological mechanisms 
involved and on drugs targeted towards 
the gastrointestinal tract is receiving 
significant attention. Some experts 
believe IBS will turn out to represent 
a series of poorly understood organic 
diseases [4]. Others caution against 
this “organification” of IBS and find it 
unlikely that an altered gene or set 
of specific biological etiologies will 
explain a complex brain–gut disorder 
such as IBS [5]. One phenomenon to 
support this cautious approach is the 
“comorbidity” aspect of IBS: patients 
with IBS report other gastrointestinal 
symptoms (such as heartburn and 
dyspepsia), somatic symptoms (such as 
musculoskeletal pain and headache), 
and psychiatric symptoms (anxiety 
and depression) more often than those 
without IBS [6,7]. Referred patients have 
the highest levels of comorbid symptoms 
and disorders. In contrast to the Rome 
III report, recent evidence shows that 
somatic and psychiatric comorbidity is a 
feature of IBS and not only of those with 
the condition who consult physicians 
[7]. The etiological implications of the 
observed comorbidity need further 
elucidation. The comorbidity of IBS also 
explains a large part of the reduced 
quality of life and increased use of health 
resources hitherto attributed to IBS [1,7]. 
Optimal care for patients with IBS will 
therefore often require physicians to 
look beyond the gastrointestinal tract. 
The comorbidity of IBS underlines the 
need for continuous and optimal care 
to be delivered to these patients by 
family practitioners. This report will focus 
on what gastroenterologists can do in 
clinical encounters with referred patients.
Making a positive diagnosis
In the absence of a biological marker, 
diagnosing IBS continues to be a 
challenge. Nevertheless, all guidelines 
recommend that IBS can and should 
be made as a positive, symptom-based 
diagnosis [8,9]. This approach requires 
a careful interpretation of the temporal 
relationship between abdominal pain/
discomfort, bowel habit, and stool 
characteristics. Diagnostic criteria 
Current challenges in  
diagnosing and treating IBS:
The importance of a positive 
diagnosis and a graded general 
treatment approach
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Table 1. Diagnostic criteria* for irritable bowel syndrome.
Recurrent abdominal pain or discomfort† at least 3 days per month the 
last 3 months associated with two or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
3. Onset associated with a change in form (appearance) of stool
*	Criteria	must	have	been	fulfilled	for	the	previous	3	months,	with	symptom	onset	at	least	6	months	
before	diagnosis.
†	Discomfort	means	an	uncomfortable	sensation	not	described	as	pain.	In	pathophysiology	research	
and	clinical	trials,	a	pain/discomfort	frequency	of	at	least	2	days	a	week	is	required	during	screening	
evaluation	for	patients	to	be	eligible	for	inclusion.
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have been established to facilitate a 
symptom-based diagnosis, with the 
Rome III criteria for IBS representing 
the latest revision (Table 1). The new 
criteria only feature minor changes from 
the Rome II list, including a simplified 
time frame and a subtype classification 
based on stool consistency. These 
criteria and a novel diagnostic 
questionnaire developed by a validation 
process can easily be downloaded from 
www.romecriteria.org. As acknowledged 
by the authors, the criteria are imperfect 
and there is a great need to generate 
data that will sharpen the criteria and 
validate their use in clinical practice. 
Interestingly, few if any studies have 
looked at how such criteria should be 
used in busy clinical practices [10,11]. 
However, the success of a positive 
diagnosis probably relies more on 
gastroenterologists’ attitudes and 
knowledge than on the strict use of 
criteria.
The positive symptom-based 
approach is preferred because it allows 
explanation, reassurance and education 
of the patient and reduces the need for 
costly and potentially harmful diagnostic 
evaluations [9,12]. Indeed, a confident 
diagnosis may be the physician’s 
most important therapeutic tool and is 
considered a cornerstone in the general 
treatment approach (see below). 
Importantly, although this approach 
differs from a traditional “diagnosis of 
exclusion” approach, it does not rule out 
the need for additional investigations 
before a diagnosis of IBS is reached in 
every patient.
Providing a graded general 
treatment approach
In a harmless disorder such as IBS, 
symptoms may range from negligible 
to incapacitating. In the absence 
of curative treatment, symptomatic 
and supportive treatment is the 
goal. The guidelines recommend a 
graded general treatment approach, 
key elements of which are a strong 
physician–patient relationship, 
assessment of psychosocial factors, 
and targeted treatment in selected 
patients [8,9].
The establishment of a strong 
and therapeutic patient–physician 
relationship hinges on thorough 
evaluation and on reassurance 
and education of the patient. The 
patient-physician encounter in IBS 
is challenging and can be frustrating 
to both parties. As the guidelines in 
Table 2 show, a structured approach 
is therefore recommended for 
establishing a therapeutic relationship. 
A quick look at these guidelines 
shows that gastroenterologists need 
to invest both time and interest. A 
therapeutic relationship will facilitate the 
assessment of psychosocial factors, 
which should include symptoms of 
depression and anxiety, somatic 
comorbid symptoms, health beliefs, 
coping, illness impact, and health-
related quality of life. Another important 
dimension is the exploration of 
chronological “coincidences” between 
psychosocial factors and periods of 
worsening or improving symptoms. In 
patients with severe symptomatology, 
referral to a skilled psychiatrist or 
psychologist can be useful. Rome III 
suggests “red flags” for consideration 
of early referral to a mental health 
care provider. In addition to severe 
depression, some other red-flag items 
include chronic refractory pain, severe 
disability, and difficulties in physician–
patient interaction.
Patient education is facilitated by 
written materials, which can be effective 
interventions in themselves. In patients 
with IBS in the United Kingdom, a self-
help handbook reduced the use of 
health care and of perceived symptom 
severity [13]. We should make such 
handbooks available to our patients. 
In my experience, patients warmly 
welcome detailed information, and such 
books reduce my workload. Some of 
these books can also be recommended 
for physicians. I have learnt a lot from 
reading Nicholas Talley’s Conquering 
Irritable Bowel Syndrome [14].
Whereas patients with mild 
symptoms are likely to benefit from the 
above general treatment approach, 
patients with more severe symptoms 
will often need targeted treatment for 
their most troublesome symptoms. 
A detailed review of such treatment 
is beyond the scope of this report. 
In general, drugs help only some 
symptoms in selected patients, and 
there is a notable placebo effect. Novel 
drug treatments such as serotonin-
receptor agonists and antagonists 
display have been disappointing, and 
they are unavailable in most European 
countries. While we are waiting 
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Table 2. Guidelines for establishing a therapeutic 
physician–patient relationship.
Obtain the history through a nondirective, nonjudgmental, patient-centered interview
Conduct a careful examination and cost-efficient investigation
Determine how much the patient understands about the illness and what his or her concerns 
are (“What do you think is causing your symptoms?”)
Provide a thorough explanation of the disorder that takes into consideration the patient’s 
beliefs
Identify and respond realistically to the patient’s expectations for improvement (“How do you 
feel I can be helpful to you?”)
When possible. provide a link between stressors and symptoms that are consistent with 
the patient’s beliefs—(“I understand you don’t think stress is causing your pain, but the pain 
itself is so severe and disabling that it’s causing you a great deal of distress”)
Set consistent limits (“I appreciate how bad the pain must be, but narcotic medication is not 
indicated”)
Involve the patient in the treatment (“Let me suggest some treatments for you to consider”)
Make recommendations consistent with the patient’s interests (“Antidepressants can be 
used for depression, but they are also used to ‘turn down’ the pain and in doses lower than 
those used for depression”)
Establish a long-term relationship with a primary care provider
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for more effective drugs for IBS, 
gastroenterologists need to provide 
patients with proven effective drug 
treatment. Such treatment includes 
tricyclic antidepressants in low doses 
for abdominal pain, loperamide for 
diarrhea/urgency, and soluble fiber for 
constipation [15–18].
Mind–body treatment (psychological 
intervention) is also effective in IBS, 
although there is a shortage of high-
quality evidence [16]. Treatment 
modalities include gut-focused 
hypnotherapy, cognitive behavioral 
therapy (CBT), stress relaxation 
therapy, and interpersonal therapy. 
In particular, hypnotherapy and CBT 
have demonstrated beneficial effects 
in severely affected patients in clinical 
trials [19]. The advantages of mind–
body treatment include efficacy in 
relation to comorbid conditions in IBS, 
its absence of adverse effects, and 
the shift of the locus of control so that 
patients themselves may feel more 
able to cope with the symptoms. If the 
goal is global improvement of patients’ 
lives and reduction of health-resource 
use, then mind–body treatment 
should more often be the treatment of 
choice. A major challenge is that such 
treatment is resource-demanding and 
that it requires highly skilled therapists 
interested in IBS. In my experience, 
these therapists are not easy to find.
How are we performing today?  
Is it time to change our practices?
The recommendations for the 
diagnosis and treatment of patients 
with IBS made by Rome III are by 
no means revolutionary [20,21]. 
One would therefore expect these 
recommendations to be widely 
implemented in clinical practice. 
Unfortunately, evidence suggests that 
this is not the case and that we have a 
long way to go.
We need to improve physicians’ 
knowledge and attitudes towards 
functional gastrointestinal disorders. 
Many gastroenterologists still view 
functional gastrointestinal disorders 
as psychological disorders, or merely 
as an absence of organic disease, 
while others deny the existence of 
functional gastrointestinal disorders. 
Gastroenterologists often ascribe 
pejorative characteristics to the patient 
or show negative attitudes during 
patient encounters [8]. Rome III 
strongly advocates proper education 
of physicians, stating that functional 
gastrointestinal disorders should be 
prominent parts of undergraduate 
and postgraduate medical curricula, 
clinical training programs, and 
international symposia. There is 
probably a significant gap between 
these recommendations and current 
educational efforts in gastroenterology 
worldwide. As a hospital physician, I 
knew next to nothing about IBS before 
I became involved in IBS research.
We need to organize our clinical 
practice to set the scene for 
optimal diagnosis and treatment. 
Gastroenterology outpatient practice 
probably varies across countries 
all over the world. In Norway, 
gastroenterologists most often choose 
to perform a colonoscopy in these 
patients, based on a short referral 
note from the family practitioner. 
Accordingly, patients’ first (and 
perhaps only) clinical encounter with 
a gastroenterologist is when they 
are lying on the endoscopy table 
with their bowels emptied and anus 
facing the gastroenterologist. This 
is not the optimal setting for making 
a positive diagnosis and providing 
a general treatment approach! In 
addition, drugs administered before 
the endoscopic examination may affect 
patients’ memory and further diminish 
the value of a clinical consultation, 
which sometimes follows after the 
colonoscopy. Many gastroenterologists 
are strong believers in the therapeutic 
value of a colonoscopy with negative 
findings, but this belief is not supported 
by research evidence. In other words, 
it seems obvious that we need to 
reorganize practice if we are aiming to 
provide patients with the optimal care 
outlined above. Perhaps we should 
start with a well-conducted clinical 
consultation in patients with symptoms 
suggestive of IBS. In harmony with 
the principles of evidence-based 
health care, this approach would allow 
clinical expertise to be combined with 
patients’ preferences in the diagnostic 
evaluation. In a young patient with 
typical symptoms of IBS, a fecal 
calprotectin test might be sufficient to 
rule out inflammatory bowel disease 
[22]. Although some patients would 
need to come back for a colonoscopy, 
it is likely that a significant proportion 
of colonoscopies would be avoided. 
Gastroenterologists will, quite 
understandably, fear missed organic 
disease and an increased workload 
with this approach. We therefore need 
high-quality research evidence that 
this approach is reliable in terms of 
diagnostic validity and cost-effective 
in terms of relevant patient outcomes 
and health-resource usage. Although 
all existing evidence supports an 
approach based on a positive 
diagnosis and general treatment, there 
is urgent need for clinical research to 
improve the evidence base.
In conclusion, gastroenterologists 
face significant challenges in the 
clinical management of patients with 
IBS. The road from best evidence to 
best practice is seldom straightforward 
and involves many factors other 
than drawing up guidelines. For 
gastroenterologists, the first and 
crucial step on this road is to 
recognize that a confident diagnosis 
and a graded general treatment 
approach could be the best treatment 
we currently have to offer for many of 
our patients with IBS.
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WGN: The World Gastroenterology 
Organisation tries to take account 
of regional differences when making 
guidelines. These differences may be 
cultural, ethnic, epidemiological, or 
resource-based. Is IBS in Pakistan 
different from IBS in Europe?
Prof. Abbas: IBS is the most 
common functional disorder seen 
in our gastroenterology clinics. The 
estimated prevalence of IBS in the 
Pakistani population is 10–15%. 
However, it is not a female-dominated 
problem, as we see more men than 
women. It is common in young and 
middle-aged adults. One reason for 
the male predominance might be that 
male patients with IBS seek medical 
advice more actively in comparison 
with women, who feel uncomfortable 
about describing their bowel function 
to medical personnel. These patients 
present with upper, mid- or lower 
abdominal pain and/or bloating. Their 
symptoms improve with defecation. 
Diarrhea-predominant IBS (IBS-D) is 
more common in Pakistan.
WGN: The prevalence of irritable 
bowel syndrome in any defined 
population depends on which criteria 
(for prevalence) are applied: the Kruis 
scoring system, the Manning criteria, 
or the ROME-I, ROME-II, or ROME-
III criteria. There are those who say 
we should now discard Rome. What 
relevance do these remarks have for 
Pakistan?
ZA: Various attempts have been made 
to group together patients presenting 
with lower gastrointestinal symptoms 
in the absence of “red flag” signs 
and organic disease. The symptoms 
are abdominal pain, discomfort 
and fullness, bloating, a feeling of 
incomplete evacuation, straining, 
postprandial bowel movements, 
altered frequency or consistency, pain 
relief with defecation, and presence of 
mucus. There are various combination 
patterns, which may vary from region 
to region and from East to West. 
The component of abdominal pain 
emphasized in the Rome criteria is 
often missing. A feeling of incomplete 
evacuation is taken by many patients 
to be constipation, although their 
frequency may be more than once a 
day to overcome this. It has already 
been reported that switching from 
the Rome II to Rome III criteria 
increases the prevalence of IBS. 
Recently, our understanding of IBS 
has significantly changed. In addition 
to the brain–gut axis, dysmotility, and 
visceral hypersensitivity, we are now 
implicating bacterial and protozoal 
infections, microinflammation, and 
cytokines. In countries like Pakistan, 
where self-medication is not 
uncommon, it is not unusual to see 
patients with IBS stating that their 
symptoms improve after taking Flagyl 
(metronidazole) for 1–2 days. Due to 
the heterogeneity of the precipitating 
factors and symptoms, it’s my “gut” 
feeling that instead of following a 
particular definition, we should keep 
an open mind, perhaps by introducing 
new terminology like “irritable bowel 
overlap syndromes” (IBOS).
WGN: A recent study from India (PMID 
18541934) argues that we should be 
mindful of “patient-centered” criteria. 
Key symptoms such as diarrhea, 
constipation, bloating, and pain are 
subjective; in India, these are not 
captured adequately by the Rome 
criteria. The study suggests that the 
cultural background may affect which 
symptoms are reported and how they 
are reported. What is the relevance of 
these remarks for Pakistan?
ZA: In Pakistan, people are more 
concerned about bloating rather than 
pain, more with upper abdominal than 
lower abdominal pain, and more with a 
feeling of incomplete evacuation rather 
than true constipation. The presence of 
mucus, postprandial bowel movements, 
and clustering of bowel movements in 
the morning in IBS-D are typical.
WGN: As you know, WGO has 
developed the concept of cascades—
resource-sensitive options for diagnosis 
and treatment. This is because 
diagnostic and management resources 
differ between countries and even 
within countries. How helpful is this 
concept for you?
ZA: The WGO practice guidelines 
are written from a viewpoint of global 
Interview with Professor 
Zaigham Abbas: IBS in Asia
Prof. Zaigham Abbas of the Sindh Institute of Urology and Transplantation, 
Karachi, is a member of the team that put together the World 
Gastroenterology Organisation guideline on Irritable Bowel Syndrome 
(IBS) (see previous article). Dr. Abbas responded to questions about IBS in 
Pakistan, the importance of resource-based guidelines, and the work that 
goes into producing a WGO guideline.
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applicability and are cascade-based. 
The cascades rank different treatment 
options for diagnosis and treatment, 
depending on the resources available. 
Many developing countries have 
limited resources. Guidelines from the 
developed world become irrelevant 
if the latest investigational tools and 
treatment options recommended in 
the guidelines are not available. By 
developing cascades, we try to match 
options for diagnosis and treatment 
with the resources available in less 
privileged areas of the world, while 
keeping the recommendations as 
evidence-based as possible. We may 
incorporate the level of evidence into 
cascades, but I don’t feel that this is 
necessary.
WGN: Your contribution to the WGO’s 
IBS guideline included very important 
elements for the IBS diagnostic and 
management cascades. It is a very 
creative process—can you tell us a 
little bit more about working on the 
cascades?
ZA: When you are working in a 
developing country, you know the 
limitations, and cascades address 
these limitations. In the case of 
IBS, we always emphasize the 
need for effective physician–patient 
relationships, which do not require any 
advanced technology but rather further 
education for physicians. We should 
also avoid a shotgun approach when 
ordering investigations in the absence 
of red-flag symptoms; limited, pertinent 
investigations are enough.
I am very proud to have been part of 
the IBS review team, and I have always 
enjoyed working with WGO. I have 
worked with IDCA, the cancer division 
of WGO, and I attended a Train-the-
Trainers workshop, in Ponta Del Este, 
Uruguay, in 2005. I am also a trainer at 
the WGO Training Center in Karachi.
WGN: One complaint often heard is that 
the usual “gold standard” guidelines 
from the major medical societies follow 
evidence-based criteria, but do not take 
account of the resources available in 
other parts of the world. Do you have 
any examples that would demonstrate 
to our readers that “one-size-fits-all” 
guidelines from Europe or the USA do 
not apply 100% in Pakistan?
ZA: An example of this is the 
hepatitis B guidelines. In all the 
guidelines, it is emphasized that 
patients should be treated only if the 
alanine aminotransferase (ALT) level 
is more than two times the upper 
limit of normal and the viral load is 
over 20,000 IU for HB
e
Ag-positive 
patients and 2000 IU in HB
e
Ag-
negative patients. In Asia, we do see 
progression of liver disease below 
the limits set in these guidelines. This 
issue has been raised at international 
meetings by Asian experts, who 
presented evidence of differences 
from the Western perceptions. Now 
I can see a positive change in the 
recent European Association for the 
Study of the Liver (EASL) guidelines, 
which recommend that patients with 
any level of elevated ALT and a viral 
load over 2000 IU should be treated, 
irrespective of their HB
e
Ag status. 
The guidelines recommend pegylated 
interferon as one of the first-line 
agents for hepatitis B treatment, but 
ignore the differences in the response 
rate depending on the viral genotype. 
In Pakistan, genotype D is the most 
prevalent type; this responds poorly to 
the interferon therapy recommended 
in Western studies. So some local 
data are needed. Moreover, there is 
a possibility of variable response in 
subtypes of genotype D. Most of the 
high-quality evidence comes from the 
industry-funded studies, so we should 
not forget the possibility of publication 
bias.
WGN: What do you hope to have 
achieved 10 years from now?
ZA: I hope that in the coming years 
I will be able to have a more active 
role in WGO, helping to achieve its 
objectives of improving standards 
in gastroenterology training and 
education on a global scale. I hope to 
help raise awareness of the preventive 
aspects of gastrointestinal and liver 
diseases. And I also hope to be 
actively involved both in the teaching 
and administrative aspects of an 
institution fully devoted to looking after 
gastroenterology and liver patients.
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Introduction
IBS subclassification
Based on the patient’s specifics of their bowel habits and 
stool characteristics according to the Rome III criteria.
IBS with diarrhea (IBS-D)  
Loose stools > 25% of the time and hard stools 
< 25% of the time  
Up to one-third of cases  
More common in men
IBS with constipation (IBS-C)  
Hard stools > 25% of the time and loose stools < 
25% of the time  
Up to one-third of cases  
More common in women
IBS with mixed bowel habits or cyclic pattern (IBS-M)   
Both hard and soft stools > 25% of the time  
One-third to one-half of cases
It must be remembered, however that:
Patients commonly transition between these 
subgroupings
The symptoms of diarrhea and constipation are 
commonly misinterpreted in IBS patients. Thus, many 
IBS patients who complain of “diarrhea” are referring 
to the frequent passage of formed stools and, in the 
same patient population, “constipation” may refer to 
any one of a variety of complaints associated with 
the attempted act of defecation and, not simply, to 
infrequent bowel movements.
On clinical grounds, other subclassifications (for example 
based on symptoms) may be possible:
•
–
–
–
•
–
–
–
•
–
–
•
•
IBS with predominant bowel dysfunction
IBS with predominant pain
IBS with predominant bloating
Based on precipitating factors:   
Post-infectious IBS  
Food-induced (meal-induced)
However, the relevance of any of these latter classifications to 
prognosis or response to therapy remains to be defined.
 It must also be remembered that Rome III criteria are not 
commonly used in clinical practice. Furthermore, cultural 
issues may inform symptom reporting. For example, in India, 
a patient who reports straining or passing hard stools is likely 
to complain of constipation even if he or she passes stools 
more than once daily.
Global prevalence and incidence
The prevalence of irritable bowel syndrome (IBS) is 
increasing in countries with developing economies. Estimates 
of the prevalence of IBS vary widely in the Asia–Pacific region 
and elsewhere, depending also on which diagnostic criteria 
are used (Rome I, Rome II, Rome III, Manning, Kruis).
Studies from India for example show that Rome I criteria 
for IBS identify more patients than Rome II criteria. Reported 
prevalence includes 0.82% in Beijing, 5.7% in southern 
China, 6.6% in Hong Kong, 8.6% in Singapore, 14% in 
Pakistan and 22.1% in Taiwan. A study in China found that 
the prevalence of IBS defined by Rome III criteria in the 
outpatient clinic was 15.9%.
Although these values are generally lower than the 
prevalence of IBS in the USA (10–15%) it is predicted that the 
continuing economic development of countries will give rise to 
changes in diet and lifestyle that may increase the incidence 
and diagnosis of this disorder.
•
•
•
•
–
–
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Irritable bowel syndrome:  
a global perspective
Definition: Irritable Bowel Syndrome (IBS) is a functional bowel disorder 
in which abdominal pain or discomfort is associated with defecation or a 
change in bowel habit; bloating, distension (in some languages, these  
words may represented by the same term) and disordered defecation are  
commonly associated features.
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Different presenting features between  
East and West
As in the case of prevalence data, global information 
on presenting features also varies and comparisons 
of studies based on community data, clinical data and 
hospital statistics are fraught with difficulties.
Typical IBS symptoms are common in healthy 
population samples but the majority of sufferers 
with IBS are not actually medically diagnosed—this 
may explain apparent differences between countries 
in reported prevalence—most studies only count 
diagnosed IBS and not community prevalence.
A study in China showed that the prevalence of IBS in 
South China was higher than that reported in Beijing, 
but lower than that reported in Western countries.
Some studies in non Western countries indicate a:   
Lack of female predominance (possibly due to 
differences in access and health-care seeking 
behaviors). In South China, for example, the male 
to female ratio is only 1 : 1.25 (in comparison to 
1:2 in Western Europe).   
Close association between marked distress and 
IBS in men similar to that found in women in 
Western studies.   
Greater frequency of upper abdominal pain.   
Lower impact of defecatory symptoms on a 
patient’s daily life (but no evidence of this was 
found in China or Mexico).
Several studies suggest that, among Afro-Caribbean 
Americans, compared with white individuals:   
Stool frequency is lower  
Prevalence of constipation higher
In Latin America, constipation predominance is more 
frequent than diarrhea.
Stool frequency appears to be greater in the Indian 
community as a whole—99% passed stools once or 
more per day.
•
•
•
•
–
–
–
–
•
–
–
•
•
In Mexico 70% have anxiety, 46% depression and  
40% both.
In Mexico, IBS incurs a high economic impact due to a 
high use of medical resources.
Clinical overlap of FD and IBS according to Rome III is 
very common in China.
Psychological distress, life events and negative 
copying style may play important roles in the 
pathogenesis of IBS. Furthermore, these factors may 
also influence the individual’s illness behavior and 
clinical outcome.
Further studies need to establish:   
Importance of dietary differences among 
countries  
Different distribution of subtypes among countries  
Differences between urban and rural areas. A 
study in Israeli Bedouins, for example, suggested 
significant differences in IBS prevalence between 
desert Bedouins (5.8%) and town Bedouins 
(9.4%) using Rome II criteria.
Diagnosis of IBS
Clinical history
Pattern of abdominal pain or discomfort : 
Chronic duration  
Type of pain: intermittent or continuous  
Previous pain episodes  
Localization of the pain—well localized pain is 
atypical  
Relief with defecation or passing of flatus  
Nocturnal pain is unusual and is considered a 
warning sign
Other abdominal symptoms:   
Bloating  
Distension  
Borborygmi  
Flatulence
Note: Distension can be measured; bloating is a subjective 
feeling. As defined in English, bloating and distension may not 
share the same pathophysiology and should not be regarded 
as equivalent and interchangeable terms (although in some 
languages the terms may be represented by a single word). 
Nor does either necessarily imply that intestinal gas production 
is increased.
•
•
•
•
•
–
–
–
•
–
–
–
–
–
–
•
–
–
–
–
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Fig 1. World map of IBS prevalence (2000–2004) 
based on Rome II and III criteria, with Manning 
criteria in parenthesis where available. Adapted 
from: Neurogastroenterology and Motility 
2005;17:317–24.
Nature of the associated bowel disturbance:  
Constipation  
Diarrhea  
Alternation
Abnormalities of defecation:   
Diarrhea for > 2 weeks  
Mucus in the feces  
Blood in stool  
Feeling of incomplete defecation
Diagnostic cascade
Diagnostic cascade
Level 1
History, physical examination, exclusion of alarm 
symptoms, consideration of psychological factors
Full blood count (FBC), erythrocyte sedimentation rate 
(ESR) or C-reactive protein (CRP), stool studies (white 
blood cells, ova, parasites, occult blood)
Thyroid function, tissue transglutaminase (TTG) antibody
Colonoscopy and biopsy
Level 2
History, physical examination, exclusion of alarm 
symptoms, consideration of psychological factors
FBC, ESR or CRP, stool studies, thyroid function
Sigmoidoscopy
Level 3
History, physical examination, exclusion of alarm 
symptoms, consideration of psychological factors
FBC, ESR and stool examination
Cautionary note: The need for sigmoidoscopy and colonoscopy, 
should also be dictated by patient characteristics (presenting 
features, age, etc) and location ( i.e. whether in an area of high 
prevalence of irritable bowel disease, celiac disease, colon 
cancer or parasitosis or not). One could argue, for example, that 
a 21-year-old female with C-IBS-type symptoms and no alarm 
features merits, at most, celiac serology.
IBS management
Introduction
Note: With patient anxiety playing a key role, reassurance 
and education are of key importance.
There is no agreement on what is the best treatment for 
patients with moderate to severe symptoms. Bulking agents, 
loperamide and antidepressants come first.
The role of probiotics may further come to the fore but 
larger and high-quality randomized controlled trials are 
needed before more definite conclusions can be drawn about 
the benefit of, for example, Lactobacillus and Bifidobacterium. 
•
–
–
–
•
–
–
–
–
•
•
•
•
•
•
•
•
•
However, clinical evidence of efficacy is beginning to emerge. 
The importance of a clear definition of strain selection, dose 
and viability is vital.
 
Management cascade
Management cascade
Level 1
Reassurance, dietary and life-style review and 
counseling
Add quality probiotic with proven efficacy
Symptomatic treatment of:  
Pain with locally available antispasmodic, for 
more severely affected patients add low-dose 
tricyclic anti-depressant or SSRI  
Constipation with dietary measures and fiber 
supplementation progressing to osmotic 
laxatives or lactulose  
Diarrhea with bulking agents and simple anti-
diarrheals
Consider psychological approaches (hypnotherapy, 
psychotherapy, group therapy) and consultation with 
a dietitian where indicated
Add specific pharmacological agents where 
approved:   
Lubiprostone for C-IBS  
Rifaximin for diarrhea and bloating  
Alosetron for D-IBS  
Tegaserod for C-IBS
Level 2
Reassurance, dietary and life-style review and 
counseling
Add quality probiotic with proven efficacy
Symptomatic treatment of:   
Pain with locally available antispasmodic, for 
more severely affected patients add low-dose 
tricyclic anti-depressant  
Constipation with dietary measures and fiber 
supplementation  
Diarrhea with bulking agents and simple 
antidiarrheals
Level 3
Reassurance, dietary and life-style review and 
counseling
Symptomatic treatment of:   
Pain with locally available antispasmodic  
Constipation with dietary measures and fiber 
supplementation  
Diarrhea with bulking agents and simple 
antidiarrheals
•
•
•
–
–
–
•
•
–
–
–
–
•
•
•
–
–
–
•
•
–
–
–
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Introduction
Nobody knows what causes irritable 
bowel syndrome (IBS)—it is functional, 
and its etiology is unknown. It cannot 
be explained, but that does not stop us 
… we can describe it and then we can 
treat the symptoms. Recent research 
shows that fiber, antispasmodics, and 
peppermint oil are more effective than 
placebo in the treatment of irritable 
bowel syndrome (PMID 19008265). 
Antidepressants are also effective in the 
treatment of IBS. There is less high-
quality evidence on the routine use 
of psychological therapies in IBS, but 
available data suggest these may be of 
comparable efficacy (PMID 19001059). 
And probiotics? Well, the future of 
probiotics may be bright, as the most 
recent systematic review in the journal 
Gut suggests (PMID 19091823).
IBS is to be the subject of the 2009 
World Digestive Health Day (WDHD). 
As its contribution to WDHD, the World 
Gastroenterology Organisation (WGO) 
has just completed a guideline on 
IBS—an IBS review team has looked at 
the latest in IBS management, and in 
line with WGO publishing policy there 
are cascades for colleagues in resource 
constrained areas. WGO guidelines 
are not “resource-blind”—see the latest 
version when it becomes available at 
http://www.worldgastroenterology.org/
global-guidelines.html.
So let’s look at the online 
landscape—reminding ourselves 
of some useful PubMed features 
and as usual reflecting on a few 
controversial questions, this time 
about if and how different cultures 
can affect the presence and reporting 
of IBS symptoms. Finally, I want to 
share with you a fine PubMed-based 
initiative from Latin America—a virtual 
gastroenterology library with IBS as its 
first example.
Looking for IBS in PubMed
As a librarian, it took me a while to 
understand the difference between 
irritable bowel syndrome (IBS) and 
inflammatory bowel disease (IBD). So, 
not surprisingly, I turned to PubMed. 
Let’s look under “PubMed services” in 
the left-hand navigation bar and click on 
“MeSH database.” You can always get a 
definition of any MeSH term by going to 
the PubMed thesaurus, Medical Subject 
Headings (MeSH) at: http://www.ncbi.
nlm.nih.gov/sites/entrez?db=mesh. 
Type in the word which you think best 
describes what you are looking for, 
choosing a unique word rather than a 
common word, for example “irritable.”
There are two MeSH terms that 
include the word ‘irritable’: irritable 
mood and irritable bowel syndrome: 
The latter is defined as “A disorder 
with chronic or recurrent colonic 
symptoms without a clearcut etiology. 
This condition is characterized by 
chronic or recurrent abdominal pain, 
bloating, mucus in feces, and an 
erratic disturbance of defection. Year 
introduced: 2004.”
Now click on “irritable bowel 
syndrome,” and you find several 
interesting items. MeSH recognizes 
the following synonyms (called “entry 
terms”):
Irritable bowel syndromes
Syndrome, irritable bowel
Syndromes, irritable bowel
Colon, irritable
Colitis, mucous
Colitides, mucous
Mucous colitides
Mucous colitis
I also note that the term was introduced 
in 2004. How, one wonders, was the 
concept indexed before 2004? A quick 
check of the indexing history shows:
Colonic diseases (1967–1970)
Colonic diseases, functional 
(1970–2003)
What does this mean? Well, anything 
resembling what today we call IBS 
would have been indexed under 
“colonic diseases” in the period 1967–
1970 and under “colonic diseases, 
functional” in the period 1970–2003.
This is a nuisance for searchers. If 
you are in an evidence-based frame of 
mind and looking for IBS trials going 
back further than 2003, for example 
for the last 10 years, you will now have 
to stop and think a little. After all, you 
now need two strategies—one for 
randomized controlled trials (RCTs) 
•
•
•
•
•
•
•
•
•
•
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published between 1999 and 2003 and 
another for RCTs published from 2004 
to today.
Apart from building the right strategy, 
there is an additional problem. “Colonic 
diseases, functional” is a very broad 
concept, and in the period 1970–2003 
it would have been used for a number 
of varying conditions, not just IBS. 
So when searching for IBS over the 
last 10 years by combining the two 
indexing terms used for IBS over the 
last 10 years you will find that many 
of the “hits” are not relevant. The 
precision of the search goes down. 
There is no way around this other than 
“re-indexing,” and that is impossible.
Now you can search for IBS in 
PubMed – let’s have some fun and 
move on to more controversial issues.
Is there an “East–West” issue? 
Shall we “sack Rome”?
The prevalence of irritable bowel 
syndrome in any defined population 
depends on which criteria (for 
prevalence) are applied: the Kruis 
scoring system, the Manning criteria, 
or the ROME-I, ROME-II, or ROME-
III criteria (from the Rome Foundation 
at: http://www.theromefoundation.
org). Not all criteria are validated for 
all countries. Some countries are 
“still” using ROME-I, while others 
are already (!) using ROME-III. Does 
this sound a little like academic one-
upmanship to you?
These are “process-centered” 
criteria. A recent study from India 
(PMID 18541934) argues that we 
should be mindful of “patient-centered” 
criteria. Key symptoms such as 
diarrhea, constipation, bloating, and 
pain are subjective, and in India these 
are not captured adequately by the 
Rome criteria. The study suggests that 
the local culture in different countries 
may inform which symptoms are 
reported, and how.
So is IBS a Western disease? No; 
probably not. Is IBS studied from a 
predominantly Western point of view—
that is to say, described with Western- 
developed criteria? Yes, definitely! 
Is this a good thing? “For whom?” I 
hear you ask. And, speaking as a true 
librarian, I would answer: “It depends 
on who you read.”
With IBS research driven by 
available resources, there is 
(understandably, I think), a natural 
tendency for the West to “self-cite.” 
This world—for example, the world 
of the Rome Foundation, set up in 
the 1980s to develop the study of 
functional gastrointestinal disorders, 
represents the elite of the IBS research 
community. A glance at the Rome 
Foundation committees provides a 
“Who’s Who” in IBS—it consists almost 
entirely of physicians from the Western 
world.
Do we not need more representation 
from non-Western experts here? 
Medical science, especially, does not 
play out in a sociocultural vacuum, 
whether East or West. Key symptoms 
such as diarrhea, constipation, 
bloating, and pain may be experienced 
differently. The typical western IBS 
patient is often a young woman, but 
this gender characteristic has not been 
reproduced in recent studies in Asia. 
Most patients with IBS in India were 
middle-aged men in the Indian study 
mentioned above, and abdominal pain 
or discomfort (an essential ROME-III 
criterion), though frequent, were not 
universal.
Besides, what about the influence 
of diet? If we assume that different 
dietary patterns have varying 
effects on colonic motility and other 
physiological phenomena relevant to 
IBS, is it possible that the Rome-III 
criteria may only “work” in populations 
in which dietary patterns are more or 
less similar? Is this not what the old 
ceteris paribus (other things being 
equal) criterion is all about? Let me 
leave you with a stirring quote about 
Rome and functional gastrointestinal 
disorders (FGIDs) that I found in 
Neurogastroenterology and Motility  
(2007;19:793–7; PMID 17883430): “It 
is, therefore, time to marvel and be 
thankful for what Rome has left us (the 
Coliseum, its culture, the precision 
of Latin, and an appreciation of the 
prevalence of FGIDs and their impact), 
and move on! It is time to sack Rome 
and follow the Hun.”
Does culture matter?
Could the Rome Foundation not 
start an “IBS and Culture” committee? 
At the same time, could scientific and 
medical publishers not start a journal 
on comparative gastroenterology? A 
journal focusing on “nature–nurture” 
issues in key gastroenterology topics? 
Alternatively, it could be called the 
“Journal of Cultural Gastroenterology.” 
Comparison is one of the oldest 
methods in science and is truly 
heuristic.
Let’s look again at the recent large 
IBS enquiry conducted by the Indian 
Society of Gastroenterology Task 
Force (ISG), published in the Indian 
Journal of Gastroenterology in 2008 
(PMID 18541934; for the full text, click 
here). A commentary is published in 
the same issue under the title “Defining 
IBS in India: a brave new world” (PMID 
18541928; for the full text, click here).
And while we are talking “culture”—
what exactly does this mean? If 
the Rome-III criteria suggest that a 
certain percentage of Indian men have 
diarrhea-predominant IBS, but the 
self-reporting does not back this up … 
what then? And anyway (I am taking 
this from the commentary mentioned 
earlier; click here), “to base outcomes 
on a questionable recall of a subjective 
rating of discomfort makes the 
Rome criteria highly unreliable.” The 
comment compliments the ISG study 
for its courage in “not allowing itself 
to be straight-jacketed by Western-
directed criteria’ (i.e., Kruis, Manning, 
and Rome).
I know we should always try to 
stand on each others’ shoulders when 
exploring a topic (meaning we should 
take account of the existing evidence), 
but there is an issue of “false avenues” 
and paradigms that have come to 
an end, and there are questions of 
ethnicity and culture and geography as 
discussed in the literature (e.g. PMID 
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15771752 and PMID 15916618). Try a 
search in PubMed for “irritable bowel 
syndrome” and “ethnic groups.” The 
hyperlink below has stored the strategy:
Irritable Bowel Syndrome[mh]  
AND Ethnic groups[mh]
 Now come the important questions: 
Do you, the reader, feel that IBS 
presents differently in different parts of 
the world? Does culture have an effect 
on symptom reporting? Does culture 
matter? How?
The Spinelli–Henderson 
IBS Library
So, what can PubMed do for our 
IBS information needs? There are 
several ways we can stay informed 
•
about IBS research, and the Spinelli–
Henderson Virtual Library for IBS is 
the most creative one I have seen 
to date (click on the hyperlinked title 
above to access the library at http://
presentaciones.110mb.com/ibs/). Its 
functionality is based on PubMed’s 
feature of allowing a search strategy 
to be captured as a web address, and 
in this way—hyperlinking from our 
self-designed icons—we can build a 
virtual library with automatic searches 
based on embedded search strategies. 
Clicking on the red icon (for “practice 
guideline”), for example, searches 
PubMed for publications indexed with 
both “irritable bowel disease” and 
“practice guideline.” Clicking on the 
green icon (for IBS and diagnosis) links 
to full-text articles dealing with IBS 
and diagnosis. The site is, of course, 
experimental and entirely thanks to the 
voluntary efforts of two Latin American 
professors of medicine. Their initiative 
deserves wide recognition for creativity 
in using advanced PubMed features. 
Needless to say, this approach can 
also be easily applied in other areas of 
medicine.
Have a look and let me know what 
you think. Or e-mail your suggestions 
and ideas to Prof. Osvaldo Spinelli in 
Argentina (ospineli@gmail.com) or 
Prof. Eduardo Henderson in Uruguay 
(eduardo.henderson@gmail.com). 
Happy searching—and remember, IBS 
is the topic for World Digestive Health 
Day 2009.
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	As Chair of the Program Committee for 
GASTRO 2009 and as a member of 
the British Society of Gastroenterology, 
I would like to encourage all readers 
of WGN to make a note of the dates 
for the meeting (21–25 November 
2009). This will be the largest and 
most comprehensive scientific meeting 
of gastroenterologists, hepatologists, 
endoscopists, surgeons, pediatricians, 
imagers, and basic scientists that has 
ever taken place for our specialty in 
Europe. The program has both breadth 
and depth, as it has been produced by 
a consortium of organizations—namely, 
the United European Gastroenterology 
Federation (UEGF), World 
Gastroenterology Organisation (WGO), 
Organisation Mondiale d’Endoscopie 
Digestive/World Organization of 
Digestive Endoscopy (OMED), and 
British Society of Gastroenterology 
(BSG). The meeting will attract 
participants from every continent and 
will deliver the highest-quality program 
imaginable.
GASTRO 2009 will span 5 days.  
The first two will involve a postgraduate 
teaching program, which will begin 
with a plenary on the management 
of inflammatory bowel disease (IBD) 
and close with a plenary session on 
the management of gastrointestinal 
bleeding, between which four parallel 
courses on endoscopy, hepatology, 
gastroenterology and, for the first 
time, gastrointestinal surgery will be 
“sandwiched.”
The core program will begin with 
an opening plenary session, which 
will be a mix of state-of-the-art 
lectures and a selection of the “‘best 
abstracts” submitted to the meeting. 
There will be live endoscopy on each 
day, coming from India, London, and 
Rome. The scientific program will be 
approximately evenly divided between 
symposia, providing updates on 
important topics such as IBD, Barrett’s 
esophagus, viral hepatitis, colorectal 
cancer, and important developments 
in endoscopy and imaging, and free 
paper sessions consisting of oral 
presentations of new research. In 
addition, there will be a daily “clinics 
in gastroenterology and hepatology” 
session in which problem clinical 
cases will be presented and discussed 
by a team of experts, a basic science 
workshop, and eight lunch sessions 
each day in which participants will 
be able to discuss common clinical 
problems with experts. Throughout 
the meeting, there will be a young 
clinicians’ program that will bring 
gastroenterologists in training 
together from around the world.
It goes without saying that the 
Program Committee has been aware 
from the start that this is a global 
gastroenterology meeting, and the 
choice of symposia, topics, and 
speakers has therefore taken this into 
account to ensure that we address 
issues of global relevance.
London will, of course, offer an 
unbeatable range of social and cultural 
opportunities, as will the social program 
being planned to run alongside the 
scientific meeting. More details are 
available on the GASTRO 2009 website 
www.gastro2009.org. I look forward 
to seeing you there.
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GASTRO 2009 
—the place to be
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University of Sussex, 
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	GASTRO 2009 UEGW / WCOG: London program highlights
GASTRO 2009, London—a new meeting for the new millennium—will provide an extensive program including a range of 
symposia on clinical updates, the world’s best gastrointestinal and liver science, and excellent training opportunities for 
established and nascent gastroenterologists. At least 50% of the core program will consist of original research communications, 
and there will also be clinical case sessions, lunch sessions, and a poster exhibition. The Program Committee for GASTRO 2009 
is committed to delivering:
A world class array of new science in gastroenterology and hepatology
High-quality updates on the frontiers of global clinical practice
Interdisciplinary symposia on new approaches to diagnosis and treatment
Live endoscopy from around the world each day
A major emphasis on innovative, technical advances in the noninvasive management of gastrointestinal and 
hepatic disorders
Overriding emphasis on the importance of addressing both research and clinical practice issues at the global level
Eight commissioned working team reports
New research workshops on each day of the core program
A full two-day postgraduate program that incorporates gastroenterology, hepatology, endoscopy, surgery, imaging 
and other diagnostic modalities. Participants will purchase a “passport” to move around the various options that 
will be running in parallel, to allow them to “pick’n mix” according to their needs and interests.
 A more detailed format description is available in the Preliminary Program, which can be downloaded at www.gastro2009.org. 
Those wishing to receive a copy of the Preliminary Program for GASTRO 2009 should contact the GASTRO 2009 Congress 
Secretariat at secretariat@gastro2009.org, regular updates on GASTRO 2009 can be signed up for on the GASTRO 2009 
mailing list at www.gastro2009.org.
Fun Run, GASTRO 2009 UEGW / WCOG, London Sunday, November 22, 2009
Have some fun—join our run! Support a medical charity while improving your health! The Public Affairs Committee is pleased to 
announce the GASTRO 2009 Fun Run, a charitable event to be held on the occasion of GASTRO 2009 in London. Delegates 
are invited to register for the Fun Run on Sunday, November 22.  The attractive 5-km running track starts and finishes near the 
congress venue.
–
–
–
–
–
–
–
–
–
General information: 
Date/time: Sunday, November 22 2009 at 10 a.m.  
Place: ExCeL London 
Distance: 5 km  
Registration fee: € 10.00  
Participation is limited to a maximum of 1000 starters.
The registration fee includes: 
Runner’s shirt 
Start number and rental of timing chip 
Free runner’s breakfast 
Finisher medal 
Personalized finisher certificate 
Registration process: Available only online at www.
gastro2009.org. If you have your own timing chip (which 
you want to use), please have its code ready for the online 
registration process.
Payment process: Only credit card payments are accepted. 
If you do not have a credit card, please contact dm&c 
(Destination Management & Consulting Europe) directly at 
funrun09@dm-and-c.at.
The registration fee of € 10.00 will be deemed to be a 
donation and will be handed over during the award  
ceremony to the appointed organization.
November 21–25, 2009ExCeL London
London, United Kingdom
EACCME applied
www.gastro2009.org
PRELIMINARY PROGRAMMEAND CALL FOR ABSTRACTS
Fun Run
Registration fee includes
 � Runners shirt
 � Start number and rental of tim
ing chip
 � Free runners breakfast
 � Finisher medals
 � Personalised certi cate
Please note the following important deadlines for GASTRO 2009: 
•  Registration: 15 May 2009, end of early registration; 16 October 2009, end of late registration, 
•  Abstract submission: 8 June 2009, deadline for abstract and clinical case submission. Deadline for  late-breaking  
    abstract submission: 17 July 2009.
WGN: I understand that you were not 
always a gastroenterologist. Please 
tell us about your training and how you 
came to develop a specialist interest in 
therapeutic endoscopy.
Dr. Carr-Locke: I received almost no 
exposure to gastroenterology as a 
medical student, except from a surgical 
perspective. My first two experiences 
as a house officer (intern) in the British 
system were with a physician and 
surgeon interested in gastroenterology, 
where I was exposed to endoscopy in 
1972 and 1973. As a student, however, 
I had enjoyed obstetrics so much that 
I thought this would be my career path 
and I took a residency position in Ob/
Gyn. Laparoscopy was in its infancy 
at that time, but something drove me 
to return to the medical specialties to 
broaden my horizons. This coincided 
with the start of Britain’s newest medical 
school, in Leicester in 1975. The Dean 
invited me to join the Department 
of Medicine as the only lecturer in 
gastroenterology. This allowed me 
to develop basic gastrointestinal 
endoscopy skills; I was subsequently 
introduced to endoscopic retrograde 
cholangiopancreatography (ERCP) in 
Leicester in 1974. I designed and built 
three endoscopy units in Leicester 
hospitals, where I gained practical and 
research experience and developed an 
essential association with surgeons.
WGN: You were part of the “brain drain” 
from Britain. Looking back, how do you 
feel about having left the UK to work in 
the USA?
DCL: By the time I left the UK in 1989, 
the National Health Service (NHS) had 
become a very frustrating environment 
in which to work as a specialist 
dependent on expensive equipment 
and wishing to conduct research and 
develop new technology. As I started 
to travel to international conferences, 
I acquired a global perspective on our 
specialty. Invitations to look at working 
in academic endoscopy units in the 
U.S. in the late 1980s were not hard 
to accept. I was considered overly 
ambitious and a traitor to the NHS by 
many in the UK, but I knew I could 
never achieve my potential there. I do 
not regret my decision to move to the 
U.S.
WGN: You have been involved in the 
development of ERCP from the early 
days. You were an investigator in the 
first prospective, randomized clinical 
trial of ERCP with sphincterotomy for 
gallstone pancreatitis. Please share 
with us your recollections of the early 
days of therapeutic ERCP.
DCL: I shall always recall our first 
ERCP in 1974. We were not permitted 
to perform the entire procedure in 
the radiology department! We were 
required to find the papilla and 
cannulate it in our endoscopy unit, 
then move the patient to radiology 
to complete the ERCP! That only 
happened once. Our duodenoscopes 
were narrow-caliber, with small 
channels; as there was no effort to 
make them electrically insulated, 
many of us received shocks and 
burns around the optical eyepiece on 
a regular basis (there were no video 
endoscopes then). I performed over 
500 ERCPs in our first year. After 
the terrifying experience of my first 
sphincterotomy and stone extraction 
(with only basket catheters available), 
it was clear to me that this would 
become the standard method for 
treating bile duct stones. Plastic stents 
were not available until 1980. Guide 
wires, sphincterotomes, catheters, 
and baskets were all reused until 
they broke. What a difference today, 
30 years on!
WGN: With the advent of helical 
computed tomography, magnetic 
resonance cholangiopancreatography 
(MRCP) and endoscopic 
ultrasonography (EUS), there have 
been dark murmurings that “ERCP is 
dead.” How do you respond to this?
DCL: Noninvasive imaging was 
primitive when ERCP was introduced; 
now it is superlative. The need for 
diagnostic cholangiography and 
pancreatography has diminished and 
almost, but not quite, disappeared. 
However, the range and indications for 
therapeutic procedures have grown 
exponentially. As in many areas of 
gastroenterology, we can only make 
a significant impact on disease with 
therapy rather than improved diagnostic 
methods alone. ERCP now plays a 
fundamental role in the management 
of ampullary, pancreatic, and biliary 
disease. The need for expertise is the 
highest it has ever been, and there 
seems little chance that this will die.
WGN: You have traveled the world 
as an ambassador for American 
gastroenterology and gastrointestinal 
endoscopy. Can you share any “war 
stories” with us about adventures you 
have had in the process?
DCL: I cannot express enough the 
honor it is to be thought of as an 
international ambassador for our 
specialty. Since the first time my brother 
took me climbing in the Austrian Tyrol 
at age 16, I have wanted to travel, 
and have been privileged with the 
opportunity to do so in my professional 
life. One remembers incredible 
sights—from the Great Wall of China 
to the Great Barrier Reef, from the 
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Pyramids to the Grand Canyon, from 
the Himalayas to Machu Picchu—with 
all of their associated customs, cultures, 
and food. Unquestionably, however, 
the most prominent memory is of 
people and hospitality. International 
travel is not always glamorous, and 
stamina is a useful asset. One of the 
first live demonstrations with which I 
was involved lasted over 12 hours in 
90° heat, and at the end there were still 
many patients waiting to be treated!
To those critics of live endoscopy 
courses and procedures performed 
by visiting faculty, I would say that 
I have witnessed the tremendous 
stimulus that such courses have had 
on local endoscopy and the demand 
for education and training that follows. 
When working in less than ideal 
circumstances, surrounded by crowds 
of people talking in languages other 
than your own, and with a myriad of 
distractions, it is essential to maintain 
one’s focus on the patient and ensure 
the best outcome.
WGN: Congratulations on your 
recent honor, the 2007 Schindler 
Award from the American Society for 
Gastrointestinal Endoscopy (ASGE). 
Can you tell us about the award and 
what it means to you?
DCL: The Rudolph Schindler Award 
represents the highest honor the ASGE 
can bestow on one of its members for 
services to the profession. The list of 53 
previous honorees reads like the Who’s 
Who of endoscopy. So to be included in 
this list is incredible. I am enormously 
proud to have been considered for this 
award. In many ways, it recognizes 
the work my colleagues and I have 
accomplished over the last 30 years. 
Some consider this award as marking the 
end of a career, but for me it is a stimulus 
to change gears and start again.
WGN: As someone who has seen more 
of the world than most of us, what is 
your impression of the global need for 
gastroenterology and gastrointestinal 
endoscopy? How do you see WGO’s 
role in addressing global issues?
DCL: Diseases of the gastrointestinal 
tract and associated organs are very 
prominent in world health. It is clear 
that in the developing world, there 
is a tremendous need for specialist 
services, training, and equipment. Many 
governmental and nongovernmental 
private, domestic, and international 
organizations, including the WGO, 
have begun to change the delivery of 
gastrointestinal health care through 
education and training. We have seen 
the tremendous impact that diagnostic 
and therapeutic endoscopy have had 
in the West. We have a responsibility 
to address the needs of health care 
in the developing world by any and all 
means. My international activities have 
played a rather small part in this huge 
process, but the WGO has made a 
commitment to addressing these global 
needs and should be commended for it. 
I shall continue to devote a significant 
part of my professional life to spreading 
the art and science of gastrointestinal 
endoscopy wherever I am able to do so.
WGN: What major advances in 
endoscopy should we expect in the next 
5–10 years?
DCL: Gastrointestinal endoscopy is 
likely to undergo some radical changes 
in the next decade, but this will occur 
in different ways and at different rates 
in different parts of the world. We 
shall see the impact of colon cancer 
screening in parts of the world that 
have yet to implement programs such 
as those that have impacted colon 
cancer in North America and Europe. 
We shall also see the effect of wider 
availability of therapeutic endoscopy 
throughout the developing world. We 
shall also see the introduction of new 
endoscopy technologies, new imaging 
methodologies, and the ability to 
image pathology in real time, which will 
have a dramatic effect on how we use 
endoscopy. Our ability to perform real 
surgical procedures not only within the 
gastrointestinal lumen but outside it as 
well has become a reality. Undoubtedly, 
we shall see the growth of a new type 
of hybrid interventional endoscopist 
capable of performing a wide range of 
endoscopic and surgical procedures as 
part of an interventional team. These 
are certainly very exciting times to be 
involved in any aspect of endoscopy.
WGN: Finally, what advice would you 
give to a gastroenterology fellow who is 
considering endoscopy as a specialist 
interest?
DCL: All gastroenterology fellows 
learn the basics of endoscopy in their 
training, but a few have a natural talent 
to go above and beyond the majority, 
and these become the next generation 
of highly skilled endoscopists who will 
continue the tradition of advancing 
the frontiers and training others. The 
career of a gastroenterologist starting 
out today will truly be dominated by 
minimally invasive approaches to disease 
management. The potential for combining 
endoscopy with developments in human 
genomics, nanotechnology, drug and 
other therapeutic delivery tools, and 
approaches to common problems that no 
longer require a skin incision will make 
the world of endoscopy a completely 
different place 20 years from now.
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Great mentors 
Steven Silvis and 
Jack Vennes
As a Fellow in Gastroenterology at 
the University of Minnesota in the 
early 1980s (1981–84), my research 
project was on bile acid metabolism. 
With a background in pathology and 
molecular biology, I had hooked up 
with Dr. Russ(ell) Hanson, a renowned 
bile acid researcher, for my fellowship 
research project. I was on the fast 
track to becoming a gastroenterologist 
with a laboratory interest in bile acid 
regulation. However, two-thirds of the 
way into my research year, Dr. Hanson 
tragically died in a motor vehicle 
accident while on a weekend hunting 
trip. Dr. Hanson’s research was so 
specialized that no one at the University 
of Minnesota was able to take over 
his laboratory. The National Institutes 
of Health and other funding bodies 
“froze” their grants, so dozens of my 
precious assays remained (literally) 
frozen in a –80 °C refrigerator and 
never saw the mass spectrometer they 
had been destined for. Russ Hanson’s 
untimely death brought my research 
to a screeching halt, and I walked the 
halls (and the banks of the Mississippi) 
wondering, what comes next?
Two senior physicians at the 
Minneapolis Veterans’ Medical Center, 
Dr. Steve(n) Silvis and Dr. Jack Vennes 
came to me with an offer: stay an 
extra year at the end of your (2-year) 
fellowship and we’ll train you up in 
ERCP. Amazingly (in retrospect), I 
asked for the weekend to think it over. 
Fortunately, I said “Yes, please,” and 
(as they say) the rest is history. By 
blind good luck, I had stumbled onto 
a hidden treasure: two of the most 
amazing mentors a fellow could ever 
have. Steve and Jack had the patience 
of Job (more than I will ever have!) and 
enough comfort in their own abilities 
and stature that they never wanted the 
limelight. Like all great mentors, they 
took great pleasure in the achievements 
of their trainees. And there were a lot of 
them. Steve and Jack trained a whole 
generation of ERCP endoscopists.
Sadly, they are both now deceased, 
but their memory lives on. Cook, Inc., 
has generously endowed a memorial 
lecture given during the ASGE Plenary 
Session at Digestive Diseases Week 
honoring Steve Silvis and Jack 
Vennes. Always ones to push the 
envelope, Steve and Jack would be 
happy to see that the first two annual 
lectures have been on natural orifice 
transluminal endoscopic surgery 
(NOTES)—the latest endoscopic 
technology on the block.
Prof. Steven Silvis (left) and Prof. Jack Vennes.
John Baillie, B. Sc (Hons), MB, 
Ch.B, FRCP, FASGE, FACG
Wake Forest University Health Sciences 
Winston-Salem, North Carolina, USA
THE FIRST ARTICLE IN A SERIES TO COME
Every year the WGO Foundation will honour and celebrate 
mentors who have made significant contributions to 
gastroenterology on a global scale by recognising them as a 
“Master of the WGO”. A special “Masters of the WGO Fund” 
has been established to award WGO Mentor Scholar Awards 
to promising up-and-coming gastroenterologists in developing 
low-resource countries to give them the financial support to 
further their careers in digestive disease. This Scholar Award is 
uniquely directed toward supporting those talented individuals 
who are committed to furthering the care of digestive disorders 
in their home country and their training will be specifically 
tailored to optimally prepare them for their future. The Scholar 
Award will provide training at a WGO Training Center in their 
particular geographical region. Since the establishment of 
the WGO Training Centers, 1100 trainees from developing 
countries have benefited and we are working diligently to raise 
funds in support of additional awards and trainees. 
To find out more, please visit www.wgofoundation.org
WGO Scholar Awards
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President of Global Health Care 
for Procter & Gamble
As	part	of	World	Digestive	Health	Day	(WDHD)	
2009,	there	will	be	a	WGO	Summit	Task	Force	
meeting	on	“The	Global	Aspects	of	IBS.”	This	
summit	will	bring	together	leading	IBS	experts	
from	around	the	world	to	assess	the	status	
of	IBS	prevalence,	impact,	and	management	
in	different	societies	and	cultures.	In	keeping	
with	the	mission	of	the	World	Gastroenterology	
Organisation,	this	summit	aims	to	draw	attention	
to	the	global	prevalence	of	IBS,	areas	of	need,	
and	the	less	resource-privileged.
The	IBS	Summit	will	take	place	at	various	
times	during	2009,	with	the	first	meeting	being	
held	on	WDHD	itself,	29	May,	in	Cincinnati.	
Further	virtual	meetings	will	take	place	over	
subsequent	months,	leading	to	the	completion	
of	an	enduring	document	and	the	presentation	
of	the	Task	Force’s	findings	at	a	special	satellite	
symposium	at	GASTRO	2009	in	London.	
The	Summit	Task	Force	is	commissioned	
with	completing	a	consensus	statement	and	
educational	tool	for	distribution	to	all	109	WGO	
national	gastroenterology	societies	and	for	
general	dissemination.
We	are	proud	to	announce	that	Procter	&	
Gamble	shares	the	WGO’s	passion	and	mission	
for	World	Digestive	Health	Day	and	has	kindly	
agreed	to	support	the	WGO	Summit	Task	Force.
WGN: Procter & Gamble (P&G) 
has partnered with the World 
Gastroenterology Organisation (WGO) 
to support World Digestive Health Day, 
the WGO’s annual digestive health 
campaign. The focus of the campaign 
this year is irritable bowel syndrome 
(IBS). Can you tell us what P&G is doing 
in the IBS field?
Tom Finn: First, I would like to share 
that P&G is proud to be working with 
the WGO in support of World Digestive 
Health Day and the WGO IBS Task 
Force. We recognize that irritable bowel 
syndrome is a global digestive health 
issue, impairing the quality of life and 
work productivity of an estimated 7–10% 
of the world’s population. We applaud 
WGO’s efforts to raise the awareness 
of and standard of care for this global 
health problem.
P&G has one of the strongest portfolios 
of leadership brands in consumer health 
and wellness and is a leader in digestive 
health care. We have conducted a 
number of preclinical and clinical studies 
to better understand IBS and to look 
for effective treatment options. As a 
result of this work, we have launched a 
new probiotic, Bifidobacterium infantis 
35624, also known as Bifantis®, that has 
been clinically proven in two placebo-
controlled trials to be effective against 
all of the cardinal symptoms of IBS. 
The results of these studies have been 
published in Gastroenterology and in the 
American Journal of Gastroenterology. 
In addition, we are working to advance 
the understanding of IBS and to promote 
overall digestive health and wellness.
WGN: Through World Digestive Health 
Day, P&G is reaching out to patients to 
encourage them to educate themselves 
about their digestive health. What is the 
role of companies in educating patients 
about health?
TF: At P&G, we believe it is important to 
educate patients about their condition, 
helping them to understand what 
triggers their symptoms and what 
lifestyle changes they might undertake 
to manage their health. We do this in a 
number of ways, which include providing 
disease information with our products, 
maintaining web sites where patients 
can both obtain disease information 
and join patient communities to share 
their stories and provide support to 
each other, and supporting the work 
of nonprofit organizations such as the 
WGO.
WGN: Has P&G partnered with nonprofit 
organizations before? If so, tell us a little 
bit about the projects.
TF: P&G’s purpose is to improve the 
everyday lives of the world’s consumers. 
We fulfill this purpose in many ways—
through P&G brands, first and foremost, 
but also through our support of 
humanitarian, educational, and social 
cause efforts. At the corporate level, 
P&G has committed to focus on the 
development of children in need through 
our global cause, P&G Live, Learn and 
Thrive™. Millions of children around the 
world live in heartbreaking conditions. 
By strengthening current programs, 
introducing new ones, and focusing 
P&G expertise and technologies on this 
critical need, we can improve the future 
for these children. P&G Live, Learn and 
Thrive comes to life through dozens of 
programs around the world, including 
its signature program, Children’s Safe 
Drinking Water. P&G partners with a 
number of nonprofit organizations on 
many of our awareness campaigns.
WGN: How can nonprofit and for-profit 
organizations work together?
TF: The key to working together is for 
each to recognize the other’s needs. 
For example, companies must realize 
that a nonprofit organization cannot 
endorse a product without losing 
credibility and hence effectiveness in 
helping to advance the field. At the same 
time, nonprofits must recognize that 
companies are focused where they have 
a business interest. By being aware 
of each other’s needs, both can work 
together for the benefit of the patient.
WGN: Tell us a little bit about what you 
do at P&G, and what you will be doing on 
World Digestive Health Day—29 May 2009.
TF: I am the President of Global Health 
Care for Procter & Gamble. I have 
responsibility for our personal health-
care and pharmaceutical businesses 
worldwide. On World Digestive Health 
Day, it will be my pleasure to host the 
WGO Summit Task Force on “The Global 
Aspects of IBS.” I’m looking forward to 
welcoming all of the task force members 
to our Mason Business Center to kick off 
the start of this important work.
Interview with Tom Finn
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